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Abstract 
 
Background information is given in chapter 1 on protease enzymes in general along with 
information specific to the calpain enzyme and its role in human disease including cataract. It 
also discusses the importance of the β-strand conformation for substrates that are recognized 
by protease enzymes. Almost all known protease substrates bind their respective targets in a 
β-strand. An overview of the modelling methodology and the modelling programs used in 
this thesis are discussed. 
 
Descriptions of the most important X-ray crystal structures that have been downloaded 
from the Protein Database (PDB) and used in this thesis are discussed in chapter 2. This 
includes the X-ray structure 1KXR, a construct of µ-calpain that was the first structure to 
show the catalytic triad of a calpain in an active conformation. The elucidation of this 
structure was important as we have used it to develop a working model for the docking 
experiments central to the work presented here. 
 
The results from docking experiments with numerous potential inhibitors are discussed 
in chapter 3, especially those from the work of Inoue et al. These include our lead compound 
SJA-6017 and analogues. The docking experiments on these compounds were performed to 
test our enzyme model and get „baseline‟ data for subsequent docking of compounds to 
establish those members of our virtual library that may be worth synthesising. We also 
included data from docking experiments using acyclic compounds that are based on the lead 
compound and those synthesized by members of our cataract group. These include N-
heterocyclic compounds, diazo- and triazene-dipeptides and are presented along with their 
IC50 and in vivo testing results. 
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In chapter 4 data is presented from docking experiments performed on the macrocyclic 
compounds that were considered and those that have subsequently been synthesized in house 
by members of the cataract research team. The importance of the β-strand conformation is 
discussed and how the presence of the macrocycle can increase the propensity of the 
molecule in a bioactive conformation, in this case a β-strand. Many of the macrocycle 
compounds presented in this chapter are shown to favour a β-strand conformation and can 
dock into our enzyme model in such a way as to indicate they may be good inhibitors. The 
docking study is backed up by in vitro IC50 and in vivo test results. 
 
To test the effectiveness of two of our best inhibitors at crossing the cornea (the major 
barrier to ocular delivery of an inhibitor to the eye lens) an apparatus called an Ussing 
chamber which I designed to fit our requirements.The chamber was expertly constructed by 
departmental workshop staff. The Ussing chamber was designed to fit a sheep cornea 
between two chambers so that corneal diffusion of an inhibitor could take place. The amount 
of inhibitor diffusing across the cornea at different time intervals was to be determined by 
HPLC or if facilities existed by radioactive labelling.One of our best in vitro inhibitors was 
also the subject of a sheep trial at Lincoln University (Morton and Bickerstaffe) and the 
results are given. An attempt to co-crystallize several of our inhibitors into papain (a very 
similar cysteine protease to calpain) was undertaken but without success. 
 
In the two final chapters we report on two studies not involved with calpain:  
 
In chapter 6 -dehydroquinase, an enzyme which catalyses the third step in the shikimate 
pathway and a sensible drug target for designing antibiotics and herbicides was examined by 
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molecular modelling.  Docking studies were performed using PDB X-ray structures of 
dehydroquinase as the target enzyme. Inhibitors designed and synthesized in house by Dr 
Mary Gower in her PhD were docked into a model of dehydroquinase to study how they 
potentially bind the active site of the enzyme. The docking data is compared with in vitro 
testing results. 
 
In the final chapter we report a study of a cyclic pentapeptide, chrysosporide, isolated 
from a New Zealand fungus by bioactivity-guided fractionation. The planar structure was 
deduced by detailed spectroscopic analysis, and the absolute configurations of the amino acid 
residues were defined by Marfey's method. As both enantiomers of Leu occurred in 
chrysosporide, molecular mechanics calculations were applied to the analysis to distinguish 
between the possible structural isomers. Only the lowest energy conformers of the cyclo-( L-
Val-D-Ala-L-Leu-L-Leu-D-Leu) isomer could explain the observed NOEs, suggesting that 
this was the most probable amino acid sequence for chrysosporide. 
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Macrocyclic Calpain Inhibitors. Angew. Chem. Int. Ed. 2009, 48, 1455 -1458. 
 
2. Abell, A. D.; Jones, M. A.; Neffe, A. T.; Aitken, S. G.; Cain, T. P.; Payne, R. J.; 
McNabb, S. B.; Coxon, J. M.; Stuart, B. G.; Pearson, D.; Lee, H. Y.-Y.; Morton, J. D., 
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1 Introduction 
 
 
1.1 Calpain and the cataract hypothesis 
 
There have been several reports
1-10
 that cataract development results from unregulated 
Ca
2+ 
mediated degradation of lens crystallins.
 
The calpain isoform m-calpain, a cysteine 
protease, is known to be a major player in cataract formation in rodent lenses and recent 
evidence indicates that over-activation by Ca
2+
 causes cataractogenesis in other mammals.
2
   
 
m-Calpain has been isolated from human lenses
2
 and it is reasonable to hypothesize that 
elevated levels of Ca
2+
 can result from damage to the eye, such as ultraviolet light exposure, 
thereby, leading to over-activation of m-calpain and an increase in proteolysis of lens 
crystallins at specific protein sites.
2
  
 
The proteins in the eye lens, namely crystallins, are extremely soluble proteins even at 
the high concentrations found in the eye lens and form a clear crystalline array resulting from 
specific protein-protein packing.
3-10
 Any degradation of the crystallins will disrupt their 
crystalline packing and subsequent precipitation can cause formation of cataract.
3-10
 
 
Since over-activation of m-calpain is involved in the hydrolysis of crystallins and thereby 
cataract formation it is, therefore, a drug target. Inhibition of this enzyme is expected to retard 
cataract formation.
2
  
 
Calpains have also been implicated in many other degenerative diseases including 
Alzheimer's and muscular dystrophy.
11-15 
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1.2 Proteases 
 
Proteases (peptidases) are a large group of enzymes that hydrolyze peptide bonds of 
proteins and peptides. These are classified as being either endopeptidases, which hydrolyze 
the internal bonds of proteins or peptides, or exopeptidases, which hydrolyze terminal peptide 
bonds.
16
 
 
The human genome contains 23 pairs of chromosomes containing about 3,000,000,000 
base pairs. The genome contains about 35,000 genes, each gene coding for a gene product. 
Proteases account for about 700 (2%) of these gene products and some 100 (14%) of these 
are under active investigation as drug targets.
17
  
 
There are currently six types of proteases recognised; aspartic, cysteine, glutamic, serine, 
threonine, and metallo-. The first five of these are characterised by the amino acid in the 
active site of the enzyme, and the sixth, the metallo-proteases, by the presence of a bivalent 
metal ion at the active site. The metal is usually a zinc ion, but can be cobalt, iron or 
manganese.
16
 
 
The scissile bond (peptide cleavage site) defines the starting point for protease active site 
nomenclature. The enzyme subsites are numbered S1, S2, S3 (S for subsite) and so on from the 
scissile bond towards the N-terminus, and S1‟, S2‟, S3‟… moving outward to the C-terminus. 
Similarly, the amino acid residues of the peptide substrate are numbered P1, P2, P3, (P for 
peptide) and P1‟, P2‟, P3‟.
16
 This nomenclature is outlined in Figure 1.1. The S subsites are 
critical points in determining the peptide substrate specificity of each protease. Subsites have 
 1   Introduction 
8 
 
preferences for different peptide (P) substrate amino acids. Changes to P substrate amino 
acids usually alter the enzyme-substrate binding affinity. 
 
-NH-CH-CO-NH-CH-CO-NH-CH-CO-NH-CH-CO-
P2 P1 P1’ P2’
S1S2 S1’ S2’
Scissile bond
Enzyme
 
Figure 1.1: A typical protease cleavage site with bound peptide substrate showing the non-prime side (S) at the 
N-terminus and the prime side (S‟) at the C-terminus. Adapted from Hooper 2002.16  
 
Research has shown proteases to be good targets for therapeutic drug discovery because 
they are involved in key metabolic processes. These include regulating the cell cycle, cell 
growth, cytoskeletal remodelling, antigen processing and apoptosis (programmed cell 
death).
16, 18
 When these processes do not function properly it can result in diseases such as 
Alzheimer‟s and cataract.18, 19 In addition to protease targets involved in human metabolism, 
there are known protease targets of disease-causing parasites, bacteria, and viruses such as 
malaria, anthrax, and HIV, respectively. 
 
Examples of aspartic protease targets are renin and HIV which are important enzyme 
drug targets for the control of hypertension and HIV, respectively.
20, 21
 
 
The cysteine proteases have been problematic for drug design, as many of their known 
inhibitors contain an electrophilic “warhead” that binds covalently in a reversible or 
irreversible manner making the inhibitor particularily reactive. This reactivity means that they 
typically bind non-specifically to other proteins, receptors and other biomolecules in vivo. 
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This can give rise to problems with toxicity, drug metabolism and other pharmacokinetics 
(the branch of pharmacology that studies the fate of pharmacological substances in the body, 
as their absorption, distribution, metabolism, and elimination).
22, 23
 However, there is 
considerable interest in developing selective inhibitors that address these problems. Calpains, 
which are a class of cysteine protease and the focus of this thesis, are implicated in many 
degenerative diseases including Alzheimer's, muscular dystrophy, and cataract.
11, 12, 14, 15, 18, 19, 
23
 
 
Glutamic proteases, once thought to be part of the aspartic proteases, are a recently re-
classified catalytic type that has, so-far, only been isolated from fungal species of 
Ascomycota.
24
 
 
In recent years metallo-protease drug targets have included those found in the Malaria 
parasite Plasmodium falciparum,
25, 26
 those targeted to treat cancer and arthritis,
27
 and even a 
metallo-protease from the anthrax causing bacteria Bacillus anthracis.
28
 
 
The most studied of the proteolytic enzymes are the serine proteases. Typical serine 
protease targets are thrombin to treat thrombosis,
29
 viral enzyme NS3-protease to treat 
Hepatitis C,
30
 and DPP IV to treat diabetes.
31
 
 
The threonine proteases include proteasome. Inhibitors of proteasome are potential anti-
cancer drugs interacting with the proteasome-ubiquitin pathway.
32
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1.3 Calpains 
 
Calpains are a group of proteases belonging to the cysteine protease group of proteolytic 
enzymes. Strictly speaking, they belong to one of at least seven different evolutionary distinct 
groups of cysteine proteases.
33
 Some examples of these distinct groups, known as clans, are 
shown in Table 1.1. 
 
Table 1.1: Clans and Families of Cysteine proteases (adapted from Barrett and 
Rawlings, 2001).33 
Clan Family Type example PDB 
Structure 
CA C1 papain (Carica papaya) 1PE6 
 C2 calpain (Gallus gallus)  1DFO 
 C27 Leader proteinase (foot-and-mouth disease virus) 1QMY 
CD C14 Caspase-1(Rattus norvegicus) 1ICE 
 C25 Gingipain R (porphyromonas gingivalis) 1CVR 
CE C5 Adenain (human adenovirus type 2) 1AVP 
 C48 Ulp1 endopeptidase (Saccharomyces cerevisiae) 1EUV 
CF C15 Pyroglutamyl-peptidase 1 (Bacillus amyloliquefaciens) 1AUG 
CH C46 Hedgehog protein (Drosophilia melanogaster) 1AT0 
PA C3 Picornain 3C (poliovirus type 1) 1HAV 
 C37 Processing peptidase (Southhampton virus)  
PB C44 Glutamine phosphoribosylpyrophosphate amidotransferase 
precursor (Homo sapiens) 
1GPH 
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Calpains are intracellular proteolytic enzymes that are activated by Ca
2+
 
11-13
 and found 
in the cytosol of almost all mammalian cells and in other animals and fungi. Calpains belong 
to the largest clan of cysteine proteases, clan CA, a clan that contains half of all cysteine 
protease families. Cysteine proteases typically have an active site consisting of a catalytic 
dyad containing a cysteine and a histidine.
33
 Calpain itself has a catalytic triad that contains 
both the cysteine and histidine with the addition of an asparagine. 
 
In mammals there are various isoforms found, some are tissue specific, others have been 
isolated from almost all tissue types. Some tissue specific calpains include; p94 – skeletal 
muscle, Lp82 – lens, nCL-2 – stomach, nCL-4 – digestive organ, CAPN6 – placenta. 
 
The ubiquitous calpains known as µ- and m-calpain are also known as calpain I and 
calpain II, respectively, and both are well characterised.
2
 They require micromolar and 
millimolar Ca
2+
 concentrations, in vitro, for activation, respectively.  
 
m-Calpain is a heterodimer consisting of six domains and this isoform is one of the best 
characterized calpains. The closely related and similarly well characterised isoform, µ-
calpain, 
11, 12, 15
 and a construct made up of domains IIa and IIb of each of these calpains (µ-
calpain and m-calpain) have provided a valuable model for our studies.
13, 18
  
 
Both µ- and m-calpain are composed of two subunits (Figure 1.2), a large 80kD catalytic 
subunit (orange), and a small 30kD regulatory subunit (blue). The large subunit is made up of 
domains I to IV and the smaller subunit of domains V and VI. Calcium binding at DIV and 
DVI is required for activation as this brings the catalytic triad of calpain in the active site (red 
star) located at DII into the active proteolytic conformation.
2
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Figure 1.2: Schematic domain representation of m-calpain. Domains I – IV make up the large 80kD (orange) 
subunit and domains V and VI comprise the small 30kD subunit (blue). Domain II is split into IIa and IIb which 
represents the two sides of the active site cleft (red star). Calcium binding occurs in domains IV and VI which 
facilitates the activation of the enzyme. 
 
Calcium activation causes a large and significant change in the conformation of the 
active site, a change that results in the arrangement of a catalytic triad in a conformation 
essential for enzyme activity.
2
 This is depicted in Figure 1.3. 
H262
C105
N286
7.6Å
     
N296
H272
C115
3.5Å
 
Figure 1.3: Left, 1KFU, a crystal structure of calpain not in the active conformation showing a catalytic 
triad with a distance of 7.6Å between the cysteine and histidine. Right, 1KXR, a crystal structure of µ-
DIIa 
DIIb 
DIII 
DIV DVI 
DV 
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calpain that is in the active conformation showing a catalytic triad with a distance of 3.5Å between the 
cysteine and histidine. 
 
The mechanism by which the enzyme cleaves peptide substrates is shown in Figure 1.4 
below. As described above, the enzyme consists of a catalytic triad which facilitates the 
hydrolysis of amide bonds. Firstly the enzyme forms a thioacetyl intermediate which is 
subsequently cleaved by an activated water molecule to leave the cysteine in its free thiol 
state ready to cleave another amide. 
 
Enzyme
R
O
NHR'
S
H
N
N
NH2
O
CYS
HIS
ASN
H
R
O
-
NHR'
S
NH
N
NH2
+
OH
H
O
H
O
S
N
N
NH2
+
O
H
O
H
:B
R
H
H
 
 
Figure 1.4: Schematic of Cysteine protease mechanism. 
 
Calpains have specific subsite preferences for certain amino acid residues. The µ- and m-
calpains show high structural homology and, therefore, have similar subsite preferences. 
Several reviews
34-36
 on calpain inhibitors report a preference at the P1 position for leucine, the 
P2 position prefers a valine or leucine, and at the P3 position the presence of large aromatic 
residues is favourable. 
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1.4 Structure of the eye, cataract and the importance of an anti-
cataract drug 
 
The structure of the human eye in Figure 1.5 shows a cross-section with the location of 
the lens in relation to the other major parts of the eye. The lens is a specialized non-vascular 
tissue that focuses an image onto the retina which then triggers electrical impulses that are 
interpreted by the brain as vision.
2
 In the lens are protein molecules called crystallins that 
form a transparent crystalline array. Because the cells of the lens have no protein synthetic or 
degradation machinery the lens crystallins need to last a lifetime.
4
 As a consequence, any 
damage to the lens is usually permanent. Damage to the lens can occur by factors such as UV 
light and free radicals which, as described earlier, can cause an influx of Ca
2+
 into the lens. 
This over-activates calpain which, in turn, begins to hydrolyse the lens crystallins causing 
opacification. In cataract, opacification of all or part of the lens prevents or distorts visible 
light from reaching the retina, thereby reducing optical performance.
2
  
 
Age related cataract in the developed world can be easily corrected by an operation to 
remove the affected lens and replace it with an artificial lens. However, waiting lists for this 
operation can be long with quality of life suffering. Therefore, the development of a topically 
applied eye treatment in the form of an eye drop to retard the progression of cataract would 
be an important alternative to surgery. 
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Figure 1.5. Schematic cross-section of the human eye showing the location of the lens.
2
 
 
In the undeveloped world surgery to treat cataract is virtually non-existant and sufferers 
spend their latter years in a blind state. A cheap eye drop treatment to retard cataract in these 
countries would prevent a lot of suffering. 
 
1.5 The β-strand: important for protease recognition 
 
It has been reported in the literature and this study has confirmed that protease substrates, 
including most peptidomimetic inhibitors of proteases, bind in a β-type strand conformation 
in the region of the active site.
37-41
 
 
The X-ray crystal structures (1TL9 and 1TL0) of truncated calpain enzymes, co-
crystallized with two well known calpain inhibitors, have been deposited in the Protein 
Database (PDB).
42, 43
 These and many other X-ray crystal structures of proteases found in the 
ever expanding PDB support the assumption that the inhibitors bind the active site in a β-
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strand conformation. This conformation facilitates the formation of several hydrogen bonds, 
and results in the formation of a mini β-sheet with active site residues (Figure 1.6 and 1.7). 
 
Figure 1.6: Diagram of a typical peptidomimetic ligand docked in the active site of mini µ-calpain according to 
the X-ray structure (PDB 1KXR) before attack from CYS 115. The formation of β-sheet type H-bonding 
between the ligand and the backbone of two GLY residues seems to be a requirement of good binding and, 
therefore, good inhibition. In addition, the electrophilic end (e.g. the aldehyde) needs to be in a position for 
nucleophilic attack by the S of CYS 115, typically within 5 Å. 
 
 
 
These H-bonds are formed between the ligand and two glycine residues in the active site 
(Gly208 and Gly271) and are important for stabilisation of the bound ligand. Bound in this 
way the ligand‟s warhead is in a position for nucleophilic attack by the active site cysteine 
(Cys115). 
N
N
R
3
H
O
H
H
O
O
NH
NH
O
HN
GLY 208 
backbone
GLY 271
backbone
S-
SER 115 CYS
R2
R1
Ligand
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A) B) 
Figure 1.7: A) Picture of a typical peptidomimetic ligand bound to active site of X-ray structure of mini µ-
calpain (PDB 1KXR) before attack from CYS 115. Note the amino acid side chains of the ligand have been 
omitted for clarity. B) A surface picture of the same X-ray structure with ligand bound. 
 
1.6 Computer modelling programs 
 
The computer-based rational design of new therapeutic agents is now possible and 
popular because of the availability of faster and cheaper computers, state of the art effective 
software, and a plethora of enzyme X-ray structures (potential drug targets). 
  
Molecular mechanics programs such as Macromodel
44-48
 are extremely useful and indeed 
such programs are crucial for rational drug design and development.
49
 They can first be used 
to search the conformational space of potential drug candidates. The ensemble of low energy 
conformers generated by a conformational search can then be subjected to cluster analysis, 
performed by programs such as Xcluster.
50, 51
 X-cluster has been written by Dr D. Quentin 
McDonald in conjunction with Schrodinger. Quentin is a former graduate of our Canterbury 
modeling group. His program greatly reduces the number of distinct conformers one has to 
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deal with by sorting closely related conformers into clusters. Representative conformers 
(determined by the Xcluster program) from each cluster can then be analyzed visually and 
statistically against conformations (computational or X-ray) of known inhibitors for their 
drug potential. MacroModel has proved to be reliable in reproducing the bioactive 
conformations of many enzyme inhibitors.
49
  
  
A particularly useful advent is that of automated docking programs, which use existing 
X-ray structure coordinates of an enzyme to explore how a potential inhibitor might bind.
52-54
 
The information obtained from these experiments give clues about which inhibitors could 
bind to the enzyme best, and thus, which ones should be synthesized. Glide is an automated 
docking program that allows small ligands to be flexibly and optimally docked to a 
protein/enzymes 'active site'.
55
 Each docked ligand has a score calculated based on specific 
parameters and a specified number of best fit conformers is kept for each ligand. The best fit 
conformers, called “poses”, can also be analyzed visually and statistically (superimposition 
using root mean square deviations of atomic coordinates) and compared to any enzyme-
ligand co-crystallized structures that are available. This can be valuable for determining any 
features of binding that may be essential for an inhibitor to be effective at binding the 
enzyme.  
 
A potential flaw in automated docking programs is that, while the ligands are treated as 
flexible molecules, the protein is treated as a rigid entity. It is, however, well known that 
many enzymes and receptors have somewhat flexible active sites in order to accommodate 
their respective substrates. It is well accepted that the Ca
2+
 activated calpains undergo 
considerable and important changes in their conformation upon Ca
2+
 binding and further 
changes occur in the active site when a substrate binds.
12, 13, 18, 56
 When the software 
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accommodates this, it is known as an induced fit docking protocol and Schrodinger‟s 
InducedFit Docking Protocol is used extensively in this thesis.
57, 58
  
   
The InducedFit Docking Protocol uses a combination of Glide
59
 and a protein structure 
prediction, preparation and refinement program called Prime.
60
 An InducedFit Docking job is 
actually a series of Glide and Prime jobs that simulate the flexible movement of both enzyme 
and ligand. 
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2 Development of a calpain model for docking studies 
 
2.1  Introduction 
 
2.1.1 Overview of calpain model development 
 
My work has involved the use of the modeling programs MacroModel (molecular 
mechanics),
1-5
 Xcluster (cluster analysis),
6, 7
 Glide (automated docking),
8, 9
 Prime (protein 
structure prediction, preparation and refinement),
10
 and the InducedFit Docking Protocol (a 
combination of Glide and Prime to induce protein flexibility while docking ligands).
11, 12
  
 
A methodology has been devised that can be applied specifically to the calpain/cataract 
problem:  
 
(i) The calpain enzymes and other cysteine proteases in the Protein Data Bank (PDB)
13
 
have been identified, and the active sites in each examined in detail. All the calpain 
structures that were available at the start of my studies were found to be in a non-active 
conformation, however, several other cysteine proteases, such as papain, have the 
catalytic triad in the active conformation. 
 
In the active conformation the cysteine proteases facilitate peptide hydrolysis of 
specific sites in a protein target. Soon after the project commenced , the structural data 
of two calpain constructs (PDB code 1KXR and 1MDW) that display an active catalytic 
triad conformation, were deposited in the PDB.
14, 15
 This was timely for our research. 
These two constructs consist of only domains I and II of µ-calpain and m-calpain, 
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respectively. IKXR was chosen for further study because this construct displayed 
activity in vitro whereas 1MDW did not. 
 
(ii) The literature was examined to establish what was known about the mechanism of 
cysteine protease (calpain) peptide hydrolysis and in particular the role of the catalytic 
triad of the active enzymes.
16-18
 This mechanistic information has allowed me to use the 
X-ray structural data and prepare a model of the active site of a calpain enzyme. 
Quantum mechanical studies of the mechanism of cysteine protease hydrolysis  has also 
been used to prepare the model for subsequent docking. The mechanism of action of 
cysteine protease being one where the active site thiol is first deprotonated and the 
active site histidine protonated upon the binding of a substrate.
16-18
  
 
 
2.2 Calpain X-ray crystal structures 
 
2.2.1 The first published structures 
 
The first X-ray crystal structures of calpain (1AJ5 and 1DVI) were deposited in the 
PDB
13
 by Blanchard et al
19
 in the late 1990‟s. The structures were not of the complete 
enzyme but of the Ca
2+
-binding domain VI of rat m-calpain in the absence of Ca
2+
 (PDB code 
1AJ5) and with Ca
2+
 bound (1DVI). The X-ray structures revealed that domain VI contained 
five EF-hand motifs and that three of them are bound to Ca
2+
. EF-hands are helix-loop-helix 
structural motifs which are known to commonly bind Ca
2+
. The presence of structural 
changes induced by Ca
2+
 binding at the EF-hands gave critical insights into how Ca
2+
 binding 
causes activation of calpain. As already mentioned it is now known that Ca
2+
 binding to 
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domain VI (Figure 2.1) and the structurally similar domain IV, induces structural changes in 
the active site which are necessary for activation of the enzyme.  
 
Lin et al
20
 went one step further and solved the structure of domain VI of porcine m-
calpain with Ca
2+
 bound (1ALV) and with Ca
2+ 
and an inhibitor PD150606 bound (1ALW).  
The inhibitor, PD150606 (3-(4-iodophenyl)-2-mercapto-(Z)-2-propenoic acid) (Figure 2.2) 
was earlier discovered and proposed to be a non-active site inhibitor by Wang et al.
21
 It binds 
into a hydrophobic pocket created by three helices (right Figure 2.1) and this pocket was 
later discovered to be where residue Phe610 of calpastatin (the endogenous calpain inhibitor) 
also binds.
22
 
 
  
Figure 2.1: Left – Cartoon ribbon diagram of domain VI of rat m-calpain in the absence of Ca2+ (blue ribbon) 
superimposed on domain VI of rat m-calpain with Ca
2+
 bound (pink ribbon) (Ca
2+
 = pink spheres). Right – 
Cartoon ribbon diagram of domain VI of porcine m-calpain with Ca
2+
 bound (green ribbon) superimposed on 
domain VI of porcine m-calpain with Ca
2+ 
and an inhibitor bound (blue ribbon) (Ca
2+
 = pink spheres, PD150606 
= red tube). 
 
 
 
Figure 2.2: Structure of PD150606 
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The first crystal structure of an entire calpain heterodimer was reported by Hosfield et al 
in 1999.
23
 The structure was of rat m-calpain in the absence of Ca
2+
 (1DFO) and confirmed 
for the first time that the catalytic triad was not in an active conformation when Ca
2+ 
was 
absent.  Ca
2+
 is required to be present for activation to occur. This structure (1DFO) was soon 
followed by the publication of two structures of human m-calpain (1KFU and 1KFX) both in 
the absence of Ca
2+
 and these confirmed the existence of a disrupted active site for the apo-
enzyme.
24
 
 
There are severe problems associated with co-crystallising native µ-calpain and m-
calpain in the presence of Ca
2+
 because they are autoproteolytic (autocatalytic enzymes), 
meaning they literally chop themselves into fragments which renders them inactive.
14, 15, 25
 
This autocatalysis is part of the enzymes natural cycle of activation and regulation by factors 
such as Ca
2+
, calpastatin, the interaction with lipids/membranes, and activator proteins. 
Autocatalysis therefore makes it impossible to obtain a crystal structure of native 
heterodimeric calpain with Ca
2+
 bound and, hence, in an active conformation. This fact also 
makes it impossible to obtain a structure with an inhibitor bound into the active site of native 
heterodimeric calpain. 
 
2.2.2 Calpain constructs 1KXR and 1MDW 
 
A breakthrough was made in 2002 when Moldoveanu et al
14
 crystallised the protease 
core of µ-calpain (1KXR) with the active site Cys115 mutated to Ser115 in the presence of 
Ca
2+
. The construct was mutated by Moldoveanu et al
14
 from Cys115 to Ser115 to inactivate 
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the construct (prevent autolysis) during crystallization. The protease core of this mutated µ-
calpain consists of domains I and II which contain the active site of the enzyme.  
 
The non-mutated construct, analogous to 1KXR, is generated during autolysis as a stable 
calpain fragment. Moldoveanu showed that this non-mutated µ-I-II construct is inactive in the 
absence of Ca
2+
 but active in the presence of Ca
2+
 when tested in vitro.  
 
Examination of the active site of the mutated construct (1KXR) showed that the catalytic 
triad was in a conformation analogous to that seen in other non calcium activated cysteine 
proteases, including papain. 
 
Figure 2.3: The active site of µ-calpain construct (1KXR) with grey carbons, superimposed on active site of 
papain (1PPN) with green carbons. Residues named are for 1KXR, including the catalytic triad of Cys115 
(mutated in silico from Ser115), His272, and Asn296. The equivalent papain residues are Cys25, His272, 
His159, and Asn175, respectively. 
 
The active site of the µ-calpain construct (1KXR) with cysteine 115 mutated to serine 
115 superimposed on the active site of papain (1PPN) is shown in Figure 2.3. The two active 
sites show striking similarity, emphasized by the close superimposition of critical residues 
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including the catalytic triad of Cys115 (papain Cys25), His272 (papain His159), and Asn296 
(papain Asn175).  
 
For our studies the crystal structure (1KXR) was mutated in silico with the Ser115 
replaced by Cys115 to produce a model that approximates that of the active construct.  
 
Moldoveanu et al also crystallized the protease core of m-calpain (1MDW) in the 
presence of Ca
2+
.
15
 However, the m-calpain construct was not active in the presence of Ca
2+
 
in vitro. The crystal structure revealed that an intrinsic mechanism causes the autolysis-
generated protease core fragment of m-calpain to be inactivated through inherent instability 
of a key α-helix.15 Residues 198-201 within this helical region (α7) display no electron 
density in 1MDW which is usually seen in native m-calpain structures and in the µ-calpain 
construct (1KXR) (Figure 2.4).   
 
Moldoveanu et al
15
 proposed that the flexibility of this glycine rich region (residues 197-
203) permits the side chain of Trp106 to swing around and into the active site pocket, as is 
seen in Figure 2.5, giving a structural basis for auto-inhibition. This is not the case with other 
isoforms of calpain such as µ-calpain. 
 
 
EFWSALLEKAYAKINGCYEALSG           EGFEDFTGGIAEWYELRKPPPNLFKIIQKALEKGS         1MDW 
175                                            197     202                                                                       236 
 
 
 
EFWSALLEKAYAKVNGSYEALSGGCTSEAFEDFTGGVTEW- D-QKAPSDLYQIILKALERGS         1KXR 
185                                                                                                                                     246 
 
Figure 2.4: Part sequence of 1MDW (residues 175-236) and the equivalent part sequence of 1KXR (residues 
185-246). The red tubes indicate regions of α-helices, blue arrows indicate regions of β-sheets. The red residue 
letter codes indicate non-conserved residues between µ-calpain and m-calpain. The region in 1MDW between 
residues 197 and 202 is normally occupied by the sequence GATT in m-calpain and is missing in 1MDW as 
there was no visible electron density.
14, 15
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At the beginning of this project the µ-calpain construct (1KXR) was the only X-ray 
crystal structure of calpain in the active conformation. This structure was therefore used as a 
template to develop a model for our initial inhibitor docking studies. At the same time, papain 
was also examined in detail due to the similarity of the active site with that in calpain. There 
are many X-ray crystal structures of papain in the PDB with and without cysteine protease 
inhibitors bound in the active site and in the β-strand conformation. Many of these inhibitors 
have been shown to also inhibit both µ-calpain and m-calpain. 
 
 
Figure 2.5: left – active site of 1KXR (grey) superimposed on active site of 1MDW (green) showing Trp116 of 
1KXR in the active conformation and the equivalent Trp106 of 1MDW blocking the active site. Right - active 
site of 1KXR (grey) superimposed on active site of 1MDW (green) showing the α7 helix of 1KXR intact and the 
equivalent region of 1MDW in a disordered state with missing residues due to no observable electron density. 
 
2.3 Exploring the calpain construct 1KXR to develop a viable 
model for Glide docking experiments 
 
The X-ray crystal structure 1KXR, the first structure of calpain with the active site in an 
active conformation was the only such structure available early in this project. The active site 
of 1KXR was explored using Schrodinger‟s molecular modeling suite. 
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The coordinates of 1KXR were downloaded from the PDB and imported into Maestro
26
, 
Schrodinger‟s graphical interface. The structure was „cleaned up‟ by deleting all the water 
molecules (this is generally performed as solvation effects are considered in the empirical 
scoring function, however, specific waters may be included when they form a bridge between 
ligand and protein) and deleting the second molecule of the dimer (chain B) to leave the 
monomer (chain A) from the crystal structure. Hydrogens were added to this chain A and the 
active site Ser115 mutated in silico to Cys115 in order to produce a structure that resembles 
the active site of the native enzyme. As shown from ab initio studies the active site thiol is 
thought to be deprotonated and the active site histidine protonated upon the initial binding of 
a substrate.
16-18
 Deprotonation of Cys115 and protonation of His272 was performed in silico 
to simulate this mechanistic change upon ligand binding. The rationale here is that the 
deprotonated cysteine model would approximate the active site at the point immediately 
before nucleophilic attack. A full description of the model refinement is described in 
Protocol 1 in the Appendix. The output structure of this minimisation was subsequently used 
for docking experiments and is referred to in this thesis as the Glide model. 
 
The Glide model was examined in detail before docking experiments were performed to 
familiarise myself with the enzymes features, especially the active site and surrounding 
residues. Figure 2.6 shows the active site of the Glide model. It is a narrow cleft bordered by 
two steep sides which are made up of domain I (left side of each picture) and domain II (right 
side of each picture). The two ends of the cleft, with Cys115 being the starting point, are 
known as the prime side and the non-prime side. The non-prime side is where most of the 
known inhibitors of calpain bind the enzyme. 
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Figure 2.6: Left – Surface diagram of 1KXR (Glide model) showing the active site cleft (black line) with the 
active site Cys 115 in yellow. Above Cys 115 is the non-prime side and below is the prime side. Right – A close 
up diagram of the top left diagram. The active site is a deep valley with high sides.  
 
     
Figure 2.7: Left – Copper areas depict regions of space on the surface of the enzyme that are hydrophobic. Deep 
within the non-prime side are areas of hydrophobicity. Right – Pale blue areas depict regions of space on the 
surface of the enzyme that are hydrophilic. Some surrounding areas just out of the pocket are hydrophilic. 
 
Deep within the non-prime region are areas of hydrophobicity which can be seen in the 
left picture of Figure 2.7 depicted as copper coloured regions. These regions are likely to 
accommodate hydrophobic amino acid side chains of a bound ligand. 
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Areas of hydrophilicity can be seen in the right picture of Figure 2.7 as pale blue areas 
surrounding the active site. These areas could accommodate hydrophilic groups of an 
inhibitor when bound into the active site. 
 
The amino acid residues that surround the non-prime region of the active site are shown 
in Figure 2.8. Cys115 is the active site nucleophilic residue that facilitates cleavage of 
peptide substrates. On either side of Cys115 are the residues Gly208 and Gly271 which are 
now known to form H-bonds to peptide based ligands that form the β-strand conformation but 
were suspected to be involved earlier based on co-crystallised structures of other cysteine 
proteases such as papain with inhibitors bound. The three H-bonds formed between the ligand 
and these two residues are thought to be essential for stabilising the bound ligand. 
 
 
Figure 2.8: Active site of the calpain Glide model based on the PDB structure 1KXR showing the residues 
surrounding the non-prime region. 
 
Di- and tripeptide based inhibitors of calpain usually have some type of capping group at 
the N-terminus which usually positions itself around the S3 subsite of the enzyme. This P3 
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subsite is surrounded by the residues Cys209, Ser251, Asn253, Lys347, and Glu349 all of 
which have H-bond donators or acceptors, therefore, capping groups which have H-bond 
acceptors or donators would likely be able to form H-bonds with these residues. Such H-bond 
formation would be favourable and likely increase the binding affinity of the ligand. 
 
2.4 The InducedFit docking model 
 
The Glide model had to be slightly modified to work with the InducedFit Protocol 
because Prime (part of the InducedFit protocol) would not allow the deprotonated Cys115 to 
work in the docking procedure. Therefore, Cys115 was left protonated in the model used for 
InducedFit docking and is referred to in this thesis as the InducedFit model. The refinement 
of the InducedFit model is described in Protocol 2 in the Appendix. 
 
2.5 Conclusion 
 
X-ray crystal structures of calpains and other cysteine proteases such as papain were 
examined in detail to gain knowledge of the calpain enzymes active site. Calpain structures 
with inhibitors bound into the active site were not available at the beginning of this project. 
However, papain, a structurally similar cysteine protease, co-crystallised with inhibitors 
bound gave insight into the way peptidomimetic inhibitors bind the active site, especially 
how they bind in a β-strand conformation and with three essential H-bonds between the 
ligand backbone and two glycine residues of the enzyme. 
 
It was also important to learn that most of the inhibitors that bind the active site of papain 
bind to the non-prime side and so it was reasonable to assume these inhibitors and their 
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analogues would bind calpain on this side. This information was critical for setting up the 
docking experiments with the aim of designing inhibitors as a docking grid of the active site 
must be produced before ligands are docked. The docking grid is a set of coordinates that 
isolates and maps the site on the enzyme to where ligands are to be docked. From these 
structures I was also able to propose modifications to known inhibitors based on the available 
space and environment around the bound inhibitors and active site. 
 
The timely release of the 1KXR structure was essential to the development of a working 
model for use in subsequent docking experiments with Glide and the InducedFit Protocol. 
This was because 1KXR was the first X-ray crystal structure of a calpain enzyme in the 
active conformation which meant that ligands could be docked in order to evaluate their 
potential as calpain inhibitors. 
 
Several structures of the calpain construct with inhibitors bound in the active site have 
recently been published. These structures have an advantage over 1KXR because their active 
sites have made subtle changes to accommodate their bound ligands and, therefore, would 
make for good models for docking experiments of similar ligands. Future work to develop 
and test such models would be an essential step to developing the next generation of calpain 
inhibitors. 
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3 Molecular modeling of acyclic inhibitors 
 
3.1 Introduction 
 
3.1.1 Natural inhibitors 
 
Among the naturally occurring calpain inhibitors is the endogenous polypeptide 
calpastatin which is found in mammalian cells along with µ-calpain and m-calpain.
1, 2
 
Calpastatin is composed of four repeating domains, which afford it the inhibitory qualities 
observed, and an N-terminal domain (domain L) that by itself displays no inhibition (Figure 
3.1).
1
 Within domains 1-4 are three highly conserved regions (regions A, B, and C). Region B 
can inhibit calpain on its own but is much more potent when flanked by regions A and C 
which are responsible for calcium dependant anchoring to calpain.
3, 4
 
 
 
 
 
Figure 3.1: Structure of calpastatin. 
 
There are also a number of calpain inhibitors derived from microbes. Many have been 
isolated from species of Streptomyces fungi including leupeptin (compound 3.1), antipain 
(3.2), and strepin P-1 (3.3).
1
 They are examples of calpain inhibitors that react reversibly with 
the active site thiol. Inhibitors of this type proved to be inadequate as biomedical tools to 
elucidate calpain cell function because they are non-selective and have poor membrane 
permeability,
1
 characteristics that also render them poor drug candidates.  
A    B   C A    B   C A    B   C A    B   C 
L 1 2 3 4 
1 706 
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Figure 3.2: Structures of leupeptin (compound 3.1), antipain (3.2), and strepin P-1 (3.3), respectively.  
 
However, the X-ray crystal structures of compounds such as leupeptin in complex with 
calpain have provided insight as to how they bind in or affect the active site of the enzyme. 
This has proved to be invaluable for the design of inhibitors. The X-ray crystal structure of 
the µ-calpain construct in complex with leupeptin (protein database 1TL9)
5
 is shown in 
Figure 3.3. The left diagram shows the inhibitor with a covalent bond between the carbon of 
the aldehyde warhead and the sulphur of Cys115. There are three hydrogen bonds between 
the leupeptin backbone and Gly271 and Gly208 of the enzyme (bonds not shown). These 
three hydrogen bonds have been found in a number of inhibitor-calpain complexes, including 
the E64 - µ-calpain construct (1TL0)
5
, SNJ-1715 - µ-calpain construct (2G8E)
6
, and ZLAK-
3001 - µ-calpain construct (2R9C)
7
, alluding to their intrinsic necessity for potent inhibition. 
 
 
 
Figure 3.3: X-ray structure of Leupeptin (3.1) in complex with µ-calpain construct (1TL9). Left – enzyme 
depicted as sticks, leupeptin as tubes. Right – Surface model of enzyme with leupeptin as tubes. 
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The right hand diagram in Figure 3.3 shows the surface of the enzyme bound with 
leupeptin. The inhibitor is stretched out along the cleft with its steep sides formed by domain 
I (righthand side) and domain II (lefthand side). It is worth noting that all of the co-
crystallised X-ray structures of the µ-calpain construct in complex with bound inhibitors were 
first reported well into my thesis work but were invaluable in confirming the earlier 
hypothesis of a β-strand and also the assumption that three H-bonds to Gly208 and Gly271 
were essential for tight ligand binding. 
 
3.1.2  Modified natural inhibitors 
 
To combat the lack of selectivity and permeability of the many natural inhibitors 
researchers first modified them by N-terminal capping with lipophilic substituents.
1
 This led 
to several compounds exhibiting cell permeability including calpeptin (3.4),
8
 MDL 28 (3.5),
9
 
calpain inhibitor I (3.6), and calpain inhibitor II (3.7) (Figure 3.4).
10
 SAR (structure activity 
relationship) data showed these compounds to be more potent and cell permeable than the 
unmodified natural inhibitors (Figure 3.2) but they lacked selectivity for calpain over other 
proteases: for example, calpain inhibitor I is more potent against cathepsin than calpain. The 
aldehyde “warheads” are all too readily oxidized under cellular conditions.1 
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Figure 3.4: Structures of calpeptin (3.4), MDL 28 (3.5), calpain inhibitor I (3.6), and calpain inhibitor II (3.7). 
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3.1.3 Lead compound: SJA-6017 
 
At the beginning of this project the compound SJA-6017
11
 was used by our research 
group as a lead compound or starting structure from which to develop calpain inhibitors that 
could be more potent or specific in vitro. As well as SJA-6017, the most potent inhibitor of 
calpain known at the time, other known inhibitors were considered to identify features that 
make for good calpain inhibition. SJA-6017 and many of the known inhibitors contain three 
regions; a warhead at one end, a middle usually consisting of two or three amino acids acting 
as a β-strand, and an address region at the opposite end to the warhead. 
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Figure 3.5:  Diagram of the three main regions of a typical calpain inhibitor. Inhibitor shown is SJA-6017. 
 
 
3.2 Docking studies of known inhibitors 
 
3.2.1 Compounds of Inoue et al  
 
The potent calpain inhibitor SJA-6017 was first synthesized by Inoue et al
11
 at Senju 
Pharmaceuticals. Their published work also reported a number of other compounds they 
prepared along with measured IC50 data against rat µ-calpain using a BODIPY fluorescent 
microplate assay.
11
 IC50 is the half maximal inhibitory concentration and measures how much 
ADDRESS 
REGION  
β-STRAND 
TEMPLATE 
WARHEAD 
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of an inhibitor is needed to inhibit a biochemical process by half. Our research group also 
uses the same BODIPY fluorescent microplate assay for measuring activity of cysteine 
proteases.
12
 (see Protocol 9 in the Appendix for description of BODIPY assay) 
 
The first docking studies were performed for Inoue‟s eighteen compounds11 for two 
reasons. Firstly, the calpain model developed for docking studies required testing to see if it 
was an appropriate model, one that could be used to assess potential inhibitors and thereby be 
used in modelling studies as a guide to the synthetic chemists in our group in choosing new 
compounds to synthesize. Secondly, the Inoue inhibitors were a series of compounds with a 
common framework but with subtle changes at various locations and with IC50 values that 
showed considerable variation with structure. Some were good inhibitors, such as SJA6017 
(compound 8 in Table 3.1), while others were only moderate and others were very poor 
inhibitors of µ-calpain. This made this series of compounds an excellent starting point for 
modelling studies to assess whether the modelling reflected how changes in structure can 
affect binding to the active site of calpain. 
 
The measured IC50‟s for Inoue‟s eighteen compounds are shown in Table 3.1. The main 
differences in structure are in the address region where different capping groups are 
employed, in the β-strand region where changes are made to side chains and in the 
configurations (L and D) of the constituent amino acids. In all cases the warhead is aldehyde. 
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Table 3.1: Structures and inhibitory concentrations (IC50) for 18 compounds from Inoue et al. 
11
 
 
Compound 
Number 
Compound Structure 
IC50 (nM) 
µ-calpain 
3.8 
 
10 
3.9 
 
14 
3.10 
 
7.5 
3.11 
 
27 
3.12 
 
23 
3.13 
 
630 
3.14 
 
31 
3.15 
 
14 
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3.16 
 
13 
3.17 
 
28 
3.18 
 
18 
3.19 
 
830 
3.20 
 
130 
3.21 
 
260 
3.22 
 
21000 
3.23 
 
14000 
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3.24 
 
42000 
3.25 
 
1000000 
 
 
 
3.2.2 Docking results for the Inoue et al compounds 
 
The compounds 3.8-3.25 were first built in MacroModel and run through a Monte Carlo 
conformational search routine using Protocol 3 in the Appendix. The lowest energy 
conformer for each compound that displayed a β-strand was then used in initiation of the 
docking studies. These conformers were docked into the active sight of the calpain model 
(Chapter 2) with Glide docking software using Protocol 4 in the Appendix. 
 
The docking parameters for the best pose
a
 (out of a possible 10 poses generated and 
collected by Glide) and the inhibitory concentrations (IC50) for the eighteen compounds of 
Inoue et al. 
11
 are shown in Table 3.2.     
 
Table 3.2: Docking data for best pose
a
 (out of possible 10) and inhibitory concentrations (IC50) for compounds 
3.8-3.25  from Inoue et al. 11 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
µ-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
3.8 -4.6 -52.1 3 3.9 200 9 0 10 
3.9 -5.4 -60.6 3 3.7 197 14 0 14 
3.10 -5.8 -49.4 3 4.2 203 9 0 7.5 
3.11 -5.9 -54.7 3 4.0 205 14 0 27 
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3.12 -4.6 -59.3 3 3.6 195 7 0 23 
3.13 -4.8 -49.9 3 4.1 139 10 1 630 
3.14 -4.5 -45.9 3 4.0 189 11 1 31 
3.15 -4.9 -55.5 3 3.7 175 10 0 14 
3.16 -6.1 -62.4 3 3.4 212 10 0 13 
3.17 -5.6 -50.7 3 3.9 216 18 1 28 
3.18 -6.0 -54.7 3 4.9 205 9 0 18 
3.19 -5.9 -48.2 3 3.7 188 9 2 830 
3.20 -4.6 -49.2 2 4.0 188 20 3 130 
3.21 -4.0 -52.7 2 3.6 212 15 0 260 
3.22 -2.4 -45.9 1 4.4 217 15 0 21000 
3.23 -4.6 -52.0 3 >5 191 15 1 14000 
3.24 -3.4 -50.9 3 4.3 233 21 10 42000 
3.25 -4.6 -46.3 2 3.8 206 13 5 1000000 
 
a
  Best pose chosen by criteria in order of importance; 1 - presence of three essential hydrogen bonds, 2 - 
warhead within 5Å of nucleophilic Cys115, 3 - low Glide score/emodel score, 4 - lowest number of internal 
ugly contacts. 
 
b
  GlideScore
13
 is a scoring function based on ChemScore
14
 which is designed to estimate free energy of binding 
for protein–ligand complex. The function uses simple contact terms to estimate lipophilic and metal–ligand 
binding contributions, a simple explicit form for hydrogen bonds and a term which penalises flexibility. 
 
c
  Emodel
13
 is a model energy score that combines energy grid score, binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy. 
 
Compounds 3.8 and 3.9 are potent inhibitors of µ-calpain. The docking data for these 
compounds demonstrates why they should be good inhibitors; they have low negative Glide 
scores and Emodel scores (see description at bottom of Table 3.2), have the three essential 
hydrogen bonds for appropriate active site binding, and have a distance between the warhead 
and nucleophilic cysteine sulphur of less than 5Å. They also have no impossibly bad internal 
contacts (termed „ugly‟ contacts in the software program Maestro) and is where the van der 
Waals contact distance is within 0.75Å. The docked poses of 3.8 and 3.9 are shown in Figure 
3.6 with the backbones (depicted as thick tubes) in the preferred β-strand conformation and 
oriented to form the three essential hydrogen bonds, one with Gly 271 and two with Gly 208. 
The naphthalene capping group of each are pointing out of the pocket and sitting over the Gly 
208 and Cys 209 residues. This is similar to how the inhibitor leupeptin (3.1) binds to the µ-
calpain construct as is seen in the PDB X-ray structure 1TL9 shown in Figure 3.3.
5
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Figure 3.6: Left – best docked poses of compounds 3.8 (blue) and 3.9 (red). Right - best docked poses of 
compounds 3.10 (blue), 3.11 (red), 3.12 (green), and 3.13 (pink). 
 
Compounds 3.10, 3.11, 3.12, and 3.13 dock into the calpain model in a similar manner to 
compounds 3.8 and 3.9 (Figure 3.6 right) but with different orientations of the 4-
fluorophenyl sulfonyl capping groups. The capping groups of 3.10 and 3.11 are pointing back 
over the β-strand backbone of the molecule, and in 3.12 and 3.13 the capping groups are 
pointing towards Lys 347. Compounds 3.10, 3.11, and 3.12 are also potent inhibitors of 
calpain and the docking data suggests why this is so; they have low negative Glide Scores 
and Emodel Scores, have the three essential hydrogen bonds, and have a distance between the 
warhead and nucleophilic cysteine sulphur of less than 5Å. Note Compound 3.10 (SJA6017) 
was made and tested by our group against ovine m-calpain (o-CAPN2) and ovine µ-calpain 
(o-CAPN1). The IC50‟s were recorded as 80nM (m-calpain (o-CAPN2)) and 130nM (µ-
calpain (o-CAPN1)) Inoue et al reported a value  of 7.5 nM against rat µ-calpain.
11
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Compound 3.13 has a poorer IC50 than compounds 3.8-3.12. The main difference 
between 3.13 and compounds 3.8-3.12 is the size of the side chain at the P1 position. 
Compound 3.13 has an alanine at the P1 position and the methyl side chain of this alanine has 
less potential for lipophilic interactions than the other compounds which have larger nonpolar 
sidechains at the P1 position. In fact compound 3.13 had the highest (less favourable) energy 
calculated for lipophilic interactions for all compounds in the series (data not shown). The P1 
side chains are in close proximity with Leu260 and are well placed to form lipophilic 
interactions with the nonpolar sidechain of Leu260. The larger P1 sidechains of all the other 
compounds also allow less movement of the compound within the active site. The best fit 
pose of compound 3.13 also has one „ugly‟ internal contact.  
 
An „ugly‟ internal contact means that the molecule has had to be forced into a slightly 
unfavourable conformation in order to fit into the active site. Within the confines of the Glide 
docking program the enzyme model is kept rigid and in reality the enzyme may be able to 
move to accommodate such a ligand so that the ligand may in fact fit without any 
unfavourable internal contacts. However, such a movement in the active site of the enzyme 
may cause the binding energy to be higher compared with ligands that do not require such an 
active site enzyme movement. The reverse can also be true such that an active site movement 
may be required for more optimal binding of a particular ligand. 
 
Compounds 3.14, 3.15, and 3.16 are good inhibitors of µ-calpain and have similar 
docking data as the other potent inhibitors discussed so far. They all have a 4-chlorophenyl 
sulfonyl capping group with their differences being at their P1 position. Compound 3.14 has a 
slightly inferior IC50 to compounds 3.15 and 3.16 and this may result from the „ugly‟ internal 
contact observed in the docking study. 
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Figure 3.7: Left – best docked poses of compounds 3.14 (blue), 3.15 (red), and 3.16 (green). Right - best 
docked poses of compounds 3.17 (blue), 3.18 (red), and 3.19 (green). 
 
Compounds 3.17, 3.18, and 3.19 can be seen docked in Figure 3.7. When compared with 
other compounds discussed above they have comparable low negative Glide scores and 
Emodel scores, the same three essential hydrogen bonds, and have a small warhead-
nucleophile distance. Compound 3.18 has the lowest IC50 of these three and the docking 
study shows no negative data. Compound 3.17 has a slightly higher IC50 which may be a 
consequence of the „ugly‟ internal contact predicted in the docking study. Compound 3.19 
has an IC50 that is more than 100 fold higher than compound 3.10 with the data showing two 
„ugly‟ internal contacts. It also has a small methyl sulphonamide capping group instead of a 
large capping group (eg 4-fluorophenyl-sulfonamide) that is seen in all the other compounds. 
This smaller non-aromatic capping group has less ability to form favourable interactions with 
the enzyme pocket than the larger capping groups which also have halogens that can form H-
bonds. 
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Compounds 3.20 and 3.21 have L-Nval and L-Nle at P2, respectively, as opposed to all 
the previously discussed compounds which have L-Val at this position. When these 
compounds dock into the active site analogously to known potent dipeptides of calpain,
5-7
 the 
P2 position fits into a deep hydrophobic pocket (S2) in the active site cleft. L-Val seems to fit 
this pocket well. L-Nval and L-Nle have longer side chains than L-Val and when these 
compounds are docked they don‟t fit the pocket as well and alter the position of the β-strand 
backbone in relation to the hydrogen bond forming Gly271 and Gly208 residues. 
Consequently both 3.20 and 3.21 have only two of the three essential hydrogen bonds and 
compound 3.20 has three „ugly‟ internal contacts possibly accounting for why these two 
compounds have IC50 values of only 130 and 260nM, respectively. 
 
Compound 3.22 is structurally similar to the most potent compound 3.10 except a methyl 
group replaces the hygrogen at the R position (Table 3.1). When 3.10 and most of the other 
compounds are docked, the hydrogen at the R position forms one of the essential hydrogen 
bonds, specifically the bond to the backbone oxygen of Gly208. The substitution of the 
hydrogen for a methyl group removes in 3.22 the potential of the ligand to form this 
hydrogen bond. The methyl group is also bulkier and forces the ligand to twist in order to fit 
into the pocket as can be seen in Figure 3.8.  As a result only one of the three essential 
hydrogen bonds is formed and the compound has a comparatively poor Glide Score of -2.4 
and consistent with the modelling a poor IC50 of 21000 nM confirming the importance of the 
hydrogen bond in this case blocked by the methyl. 
 
3   Molecular modeling of acyclic inhibitors 
 
 56 
 
 
 
Figure 3.8: Left – best docked poses of compounds 3.20 (blue) and 3.21 (red). Middle - best docked pose of 
compound 3.22 (blue). Right - best docked poses of compounds 3.23 (blue), 3.24 (red), and 3.25 (green). 
 
 
Compounds 3.23, 3.24, and 3.25 all have very poor IC50 values. These three compounds 
are the same as 3.10 except one or both amino acids have a D configuration instead of the 
normal L. Not surprisingly this difference in chirality has detrimental effects for ligand 
binding. For 3.23 a D-Leu at the P1 position means that even with the three essential hydrogen 
bonds in place such a configuration results in the electrophilic aldehyde warhead not being 
close to the nucleophilic cysteine sulphur and accordingly being unable to be involved in a 
reversible covalent bond. 
 
Compound 3.24 has valine at the P2 postion in a D configuration. The docking studies 
show that this compound could dock with the three appropriate hydrogen bonds and with a 
close warhead-cysteine distance but not without having ten „ugly‟ internal contacts. Most of 
these „ugly‟ contacts are due to the P1 and P2 side chains being impossibly close to each 
other, and the P2 side chain in an impossible proximity to the phenyl ring. The docked pose of 
3.24 in Figure 3.8 also shows that the side chain of the D-Val is pointing out of the active site 
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pocket instead of deep in the hydrophobic region of the cleft where the P2 side chain is found 
in poses of the more potent dipeptide ligands. The loss of this seemingly crucial hydrophobic 
contact is reflected by the poorer Glide score of -3.4. 
 
Compound 3.25 has both the P1 and P2 amino acids in a D configuration.  The best 
docked pose of this compound shows that it can only form two of the three required hydrogen 
bonds when the warhead is in a position for nucleophilic attack. In order to achieve this pose 
five „ugly‟ internal contacts form, most of which involve the close proximity of the P2 
sidechain and the capping group end which is an unfavourable conformation. 
 
Of the eighteen compounds docked, eight compounds (3.8, 3.9, 3.10, 3.11, 3.12, 3.15, 
3.16, and 3.18) have an IC50 of less than 30nM against µ-calpain. When docked these eight 
have poses that show a warhead-cysteine sulphur distance of less than 5Å, which is an 
appropriate distance necessary for nucleophilic attack to occur on the aldehyde and thus be in 
a position for a reversible covalent bond to form. They all meet the requirement of having the 
three essential hydrogen bonds, an important constraint of a β-strand moiety, a conformation 
observed in almost all known protease-ligand complexes.
13
 Their P1 side chains form 
hydrophobic contacts with Leu260 and their P2 side chains fit deep into the hydrophobic 
pocket of the active site. All display poses that contain no „ugly‟ internal contacts, indicative 
of not being forced into an impossible conformation in order to fit into the pocket. The 
capping groups of these eight compounds are found to be all pointing out of the pocket in 
variable positions in relation to the rest of their structure; some are folded back over the 
dipeptide backbone, some are over Gly 208, and others are pointing away from the dipeptide 
backbone. 
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The variable positioning of the capping groups is consistant with the findings of Qian et 
al where the electron density around the capping group of two α-ketoamide inhibitors was 
found to be weak within their solved X-ray crystal structures (2R9C and 2R9F), suggesting 
that they are flexible and form limited interactions with the S3 unprimed region.
7
  The X-ray 
structures of these two α-ketoamides show their capping groups sitting over Gly208 as was 
observed in the docking of several of the Inoue et al
11
 compounds. The protecting group of 
the two α-ketoamides is carboxybenzyl which has no substituents on the aromatic ring that 
can act as hydrogen bond donors or acceptors. In contrast all the Inoue et al
11
 compounds 
with the exception of compounds 3.8, 3.9, and 3.19 have either a fluorine or chlorine 
substituent on their capping group, with the the potential to form hydrogen bonds. These 
hydrogen bonds are possible at the P3 subsite residues and may possibly form between the 
capping group halogens and residues Lys347 and Asn253 with a small flexible movement of 
these active site residues. Their GlideScores are between -4.6 and -6.0.  
 
The other ten compounds have at least one of the above mentioned criteria that are less 
than satisfactory for binding (highlighted yellow in Table 3.2) and this modelling correlates 
with their inferior IC50 results. 
 
 
3.3 Docking studies of SJA-6017 analogues 
 
3.3.1 N-Heterocyclic dipeptides 
 
Our calpain research group wanted to investigate different capping groups at the P3 
position to see if additional binding could be achieved in the S3 region of calpain. A series of 
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N-heterocyclic analogues of SJA-6017 were suggested by the synthetic chemists in our 
research group and molecular modeling studies were used to first assess their potential as 
calpain inhibitors and to rationalize any differences in IC50
 
values measured for these 
compounds where it was decided it was worth synthesizing.
 
 
Ten N-heterocyclic dipeptides that were synthesized along with their corresponding 
measured IC50 results are shown in Table 3.3. The dipeptides have an aldehyde warhead and 
the same backbone as the lead compound SJA6017. The N-heterocyclic capping group varies 
at the X, R1, and R2 positions. 
 
Table 3.3: Structures and inhibitory concentrations (IC50) for ten N-heterocyclic dipeptides (3.26-3.35)    
Compound 
Number 
Compound Structure IC50 (nM)  
o-CAPN1 
IC50 (nM)  
o-CAPN2 
3.26 
 
290 25 
3.27 
 
650 315 
3.28 
 
960 100 
3.29 
 
790 135 
3.30 
 
440 85 
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3.31 
 
680 100 
3.32 
 
530 100 
3.33 
 
150 150 
3.34 
 
340 110 
3.35 
 
290 140 
 
 
3.3.2 Docking results of N-heterocyclic dipeptides 
 
The ten dipeptides were built in MacroModel
14
 and a conformational search of each was 
undertaken using Protocol 3 in the Appendix. The lowest energy conformer for each 
compound that displayed a β-strand was used as a starting structure for the docking study and 
were identified by Xcluster analysis.
15
 These low energy conformers were docked into the 
active sight of the calpain model with Glide docking software using Protocol 4 in the 
Appendix. The low energy conformers for the ten dipeptides were also used to dock into the 
calpain model using the InducedFit docking program using Protocol 5 in the Appendix. The 
3   Molecular modeling of acyclic inhibitors 
 
 61 
InducedFit Protocol was performed to compare the results with the Glide docking results to 
determine if InducedFit was a better predictive tool than Glide docking. 
 
The Glide docking data for the best pose (out of a possible 10 poses generated and kept 
by Glide) and the inhibitory concentrations (IC50) against ovine calpain 1 (o-CAPN1) and 
ovine calpain 2 (o-CAPN2) for the ten compounds are shown in Table 3.4.     
 
Table 3.4: Glide docking data for best pose (out of a possible 10) and inhibitory concentrations (IC50) of ten N-
heterocyclic dipeptides. 
 
 Glide emodel Essential Warhead Internal contacts IC50 (nM) 
Cpd
a
 score score H bonds distance Good Bad Ugly o-CAPN1 o-CAPN2 
3.26 -6.2 -54.7 3b 3.6 197 20 3 290 25 
3.27 -5.0 -49.3 3.0 4.0 177 4 2 650 315 
3.28 -5.0 -52.9 3.0 4.3 181 5 1 960 100 
3.29 -5.6 -48.4 3.0 3.7 173 5 0 790 135 
3.30 -5.3 -53.8 3.0 4.1 189 5 0 440 85 
3.31 -5.0 -46.6 3.0 3.9 177 3 0 680 100 
3.32 -5.1 -49.9 3.0 4.5 184 8 2 530 100 
3.33 -5.3 -49.9 2b 3.7 199 17 2 150 150 
3.34 -5.4 -46.7 0.0 3.5 180 9 0 340 110 
3.35 -3.2 -49.8 3.0 3.7 187 6 0 290 140 
 
a
 Compound.  
b
 Hydrogen bonds from the Gly271 carbonyl and Gly208 carbonyl and NH group to the ligand are present but 
not bonded to the usual ligand donor and acceptor groups of the ligand backbone. 
 
Compound 3.26 is potent against m-calpain (o-CAPN2) and is >11 fold more selective 
for m-calpain over µ-calpain (o-CAPN1). The docked pose of 3.26 on the left hand side of 
Figure 3.9 has the best Glide score of -6.2 and has a different binding pattern compared with 
other potent dipeptide inhibitors and this may explain why it is more potent than other 
inhibitors in this series. The essential hydrogen bond formed between Gly271 and the NH at 
the P1 position is the same as that seen in other potent dipeptides, however, hydrogen bonds 
between Gly208 and the NH and carbonyl group at the P2 position are not observed. Instead 
the ligand, in comparison with other potent dipeptides, is twisted so that hydrogen bonds are 
formed between the carbonyl at the P3 peptide bond and the backbone NH of Gly208, and 
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between the NH of the pyrrole and the backbone carbonyl of Gly208. The warhead is still 
held in a good position and orientation for nucleophilic attack by the sulphur of Cys115. 
There is an additional hydrogen bond between the P1 aldehyde and the side chain of Gln109.  
 
In spite of this unique hydrogen bonding formation, the compound loses some 
hydrophobic contacts because of the rotation necessary for the hydrogen bonds to form while 
still having a close warhead-nucleophile distance. This causes the valine sidechain to point 
out of the cleft as opposed to positioning itself deep into the hydrophobic pocket. It also 
produces three „ugly‟ contacts since the sidechains of valine and leucine are brought close 
together. 
 
 
Figure 3.9: Left – best docked pose of compound 3.26 (blue) from Glide docking. Right - best docked pose of 
compound 3.26 (red) from the InducedFit docking. Hydrogen bonds shown as dashed yellow lines. 
 
When compound 3.26 was docked using the InducedFit protocol (right hand pose in 
Figure 3.9) the result was a similar pose. The pose shows the same general orientation as that 
seen on the left of Figure 3.9 (Glide docking pose). In addition a hydrogen bond is formed 
between the aldehyde at the pyrrole end of the compound and the NH backbone of Thr210.  
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The bond between the P1 aldehyde and the side chain of Gln109 is lost and replaced with one 
between the P1 aldehyde and the side chain of His272 due to a slight change in position of the 
aldehyde within the pocket but does not change its close proximity to the nucleophile. The 
InducedFit pose still has three „ugly‟ internal contacts.  InducedFit seemingly has no benefit 
over Glide docking.    
 
Compound 3.27 is one of the least potent in the series and is only twice as selective for 
m-calpain (o-CAPN2) over µ-calpain (o-CAPN1). It forms the three essential hydrogen 
bonds when docked into the µ-calpain model using Glide and forms two additional hydrogen 
bonds when docked with the InducedFit Protocol (Figure 3.10). One additional bond is 
formed between the carbonyl at the capping group end and the side chain of Asn253. The 
other is between the NH of the pyrrole and the backbone of Gly208. It is not clear from the 
docking studies why this is not as potent as others in the series except for two „ugly‟ internal 
contacts.  
    
Figure 3.10: Left – best docked pose of compound 3.27 (blue) from Glide docking. Right - best docked pose of 
compound 3.27 (red) from the InducedFit docking. Hydrogen bonds shown as dashed yellow lines. 
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The left picture in Figure 3.11 shows the best docked poses of compounds 3.28, 3.29, 
3.30, and 3.31. These four all dock in a similar manner with all the essential hydrogen bonds 
in place with a close warhead-nucleophile proximity. Their IC50‟s are similarly potent against 
m-calpain (o-CAPN2) at around 100nM, but vary against µ-calpain (o-CAPN1). Compound 
3.28 (blue) and compound 3.31 (pink) have only the three essential hydrogen bonds in their 
respective best poses. Additional hydrogen bonding is found in the docked poses of 
compounds 3.29 and 3.30 from their respective capping groups to the enzyme. 3.29 (red) 
displays a hydrogen bond from the furan ring oxygen to the side chain of Asn253. The 
sulphur, in the thiophene ring of compound 3.30 (green), forms a hydrogen bond to Lys347 
and another from the aldehyde to the side chain of Lys347. These additional hydrogen bonds 
are favourable and would contribute to tight binding of the compounds to the active site. 
Compounds 3.28 and 3.31 also display hydrogen bonding from their capping group oxygen 
and sulphur, respectively, in other docked poses (not shown). 
 
 
Figure 3.11: Left – best docked pose of compound 3.28 (blue), 3.29 (red), 3.30, (green) and 3.31 (pink) from 
Glide docking. Right - best docked pose of compound 3.30 (green) from the InducedFit docking, Hydrogen 
bonds shown as dashed yellow lines. 
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When the InducedFit protocol was used compounds 3.28, 2.29, and 3.31 did not return 
any docked poses. Compound 3.30 returned one docked pose shown on the right of Figure 
3.11. However, the two additional hydrogen bonds seen in the Glide docked pose are not 
observed in the InducedFit pose as the side chain of Lys347 has moved. InducedFit 
modelling for these compounds has not been beneficial. 
 
Compound 3.32 shown below in Figure 3.12 (left) docked (with Glide) into the active 
cleft and shows the three essential hydrogen bonds in place and the warhead in position for 
nucleophilic attack. It is one of the most potent of compounds in the series against m-calpain 
(o-CAPN2) but is five times less potent against µ-calpain (o-CAPN1). There is one extra 
bond involving the pyrrole aldehyde and the side chain of Lys347. When docked with 
InducedFit this extra hydrogen bond is lost due to movement of the lysine residue. 
 
Figure 3.12: Left – best docked pose of compound 3.32 (blue) from Glide docking. Right - best docked pose of 
compound 7 (blue) from the InducedFit docking. Hydrogen bonds shown as dashed yellow lines. 
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Compound 3.33 docked into the active site with Glide (Figure 3.13) in an analogous 
manner to that of compound 3.26. Compound 3.33 and 3.26 have similar structures - a methyl 
group in compound 3.33 replaces the NH hydrogen in the pyrrole ring of compound 3.26. 
The methyl group in 3.33 does not allow for a hydrogen bond to form, as occurs for 3.26 
between the NH of the pyrrole and the backbone oxygen of Gly208. The methyl group being 
bulkier than the hydrogen also causes the pyrrole ring to twist in order to fit into the active 
site pocket. A H-bond does form between the pyrrole aldehyde and Lys347. This compound 
is the most potent against i-calpain (o-CAPN1) at 150nM but is unselective as it also has an 
IC50 of 150nM against (o-CAPN2).  No pose was returned when compound 3.33 was run 
through the InducedFit protocol. 
 
Figure 3.13: Left – best docked pose of compound 3.33 (red) from Glide docking. Hydrogen bonds shown as 
dashed yellow lines. 
 
The pose on the left of Figure 3.14 shows compound 3.34 docked into the active site 
using Glide. As depicted the compound does not form any of the essential hydrogen bonds 
seen in other potent dipeptide inhibitors. 
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Figure 3.14: Left – best docked pose of compound 3.34 (green) from Glide docking. Right - best docked pose 
of compound 3.34 (green) from the InducedFit docking. Hydrogen bonds shown as dashed yellow lines. 
 
On the right of Figure 3.14 is the best docked pose of compound 3.34 using the 
InducedFit Protocol. This pose is more typical of a potent dipeptide calpain inhibitor with it 
having the three essential hydrogen bonds. The capping group is unusually positioned such 
that it is twisted and pointing towards the Asn253 residue. The capping group does not form 
any additional hydrogen bonds with the enzyme. The in vitro testing revealed 3.34 to be 
reasonably potent against m-calpain (o-CAPN2) with an IC50 of 110nM, three times more 
potent than against µ-calpain (o-CAPN1). InducedFit docking of compound 3.34 was 
nessessary as Glide docking did not produced any viable poses. 
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Figure 3.15: Left – best docked pose of compound 3.35 (pink) from Glide docking. Hydrogen bonds shown as 
dashed yellow lines. 
 
Compound 3.35 displays typical hydrogen bonding for a potent dipeptide and the 
aldehyde warhead is in position for nucleophilic attack (Figure 3.15). It inhibits m-calpain 
(o-CAPN2) with an IC50 of 140nM and µ-calpain (o-CAPN1) with an IC50 of 290nM. The 
capping group displays no hydrogen bonding, although it is in a position where such bonding 
could occur if small movements in the surrounding residues facilitated this happening. There 
was no InducedFit poses returned for this structure. 
 
In summary, the ten N-heterocyclic dipeptides (compounds 3.26-3.35) are all potent or 
semi-potent calpain inhibitors as shown by their low to reasonably low IC50‟s against both m-
calpain (o-CAPN2) and µ-calpain (o-CAPN1).  Compounds 3.26, 3.28, and 3.31 are highly 
selective for m-calpain (o-CAPN2) over µ-calpain (o-CAPN1) while the rest display only 
moderate to little selectivity.  
 
All the compounds, excluding 3.26, 3.33 and 3.34, dock using Glide in an extended β-
strand conformation with the three essential hydrogen bonds intact and with adjacent 
3   Molecular modeling of acyclic inhibitors 
 
 69 
warhead-nucleophile proximity. Compounds 3.28-3.32 all have hydrogen bond acceptors in 
their capping groups that form bonds with donators from the side chains of either Asn253 or 
Lys347. These hydrogen bonds are seen in either the best poses of each docked structure or 
similar poses within the top ten poses that Glide produced. Compound 3.27 has no hydrogen 
bond acceptor in its capping group and this may reflect why it is the least potent against m-
calpain (o-CAPN2) and one of the least potent against µ-calpain (o-CAPN1). 
 
Compound 3.34 docks in an appropriate manner only using the InducedFit docking. Like 
compound 3.27 it has no hydrogen bond acceptors in its capping group. The 5-methyl pyrrole 
capping group is uniquely twisted to one side and the methyl group is pointing into a 
hydrophobic pocket formed by the enzyme residues Ile257 and Leu260 giving rise to a 
hydrophobic-hydrophobic interaction (Figure 3.16). This interaction could explain why 3.34 
is more potent than compound 3.27 which does not have the hydrophobic methyl group. 
 
 
Figure 3.16: Best docked pose of compound 3.34 (tube structure) from the InducedFit docking, The enzyme is 
shown as a surface representation with residues colour coded by residue property; green = hydrophobic, blue = 
positive, red = negative, cyan = polar uncharged, and grey = glycine.  
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The methoxycarbonyl pyrrole group of compound 3.35 has the potential to form 
hydrogen bonds with the likes of Lys347 and Asn253 but no such interactions were observed 
in any of the poses generated by Glide. The other poses generated by Glide had the 
compound docking in a similar mode to that of compound 3.26. 
 
All ten compounds showed varying degrees of potency and selectivity although the 
difference between the best and worst compound in each category was not large. Most of the 
compounds best docked poses showed the ability or potential to form hydrogen bonds with 
the residues surrounding the S3 subsite of the enzyme.  
 
Compound 3.26 has a distinctive binding mode (compound 3.35 also showed this mode 
in poses not shown). In reality it may be able to bind in the more typical manner seen in the 
other docked compounds and has the potential to form hydrogen bonds between the pyrrole 
aldehyde and surrounding residues such as Lys347. The only way to determine the actual 
mode of binding would be to undertake an X-ray crystal structure of compound 3.26 co-
crystallised with the enzyme. However, it is likely that compound 3.26 actually binds in the 
typical β-strand mode and that the manner in which it docks with Glide is a „figment‟ of the 
program. It may have two distinct ways of binding the enzyme tightly, the one shown in the 
docking and the typical β-strand mode which could explain its higher potency. If this unusual 
binding mode is in fact the actual manner in which it binds then that may be the reason for 
greater potency alone. However, this unusual binding pattern has some „ugly‟ internal 
contacts and the valine at the P2 position is pointing out of the pocket instead of it pointing 
into the hydrophobic S2 subsite which is more typical of potent di-peptides. 
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Using the InducedFit docking did not add anything to the results of the Glide docking 
except in the case of compound 3.34 which did not dock appropriately with Glide but did 
produce a viable pose with InducedFit. Therefore, it may only be nessessary to use the 
InducedFit Protocol on ligands of this type (di-peptide aldehydes) when Glide does not 
produce the expected docked poses. 
 
3.4 Docking studies of diazo and triazene compounds 
 
The following is work has been published in a paper on the modelling of diazo- and 
triazene dipeptide aldehydes; 
 
Investigation into the P3 Binding Domain of m-Calpain Using Photoswitchable Diazo- and Triazene-dipeptide 
Aldehydes: New Anticataract Agents 
Abell, A. D.; Jones, M. A.; Neffe, A. T.; Steven G. Aitken; Cain, T. P.; Payne, R. J.; McNabb, S. B.; James M. 
Coxon; Stuart, B. G.; Pearson, D.; Lee, H. Y.-Y.; Morton, J. D., J. Med. Chem. 2007, 50, 2916-2920. 
 
 
A series of (E)- diazodipeptide aldehydes (amides 3.36a-d and sulphonamides 3.37a,b) 
that contain an N-terminal diazo group designed to extend deep into the S3 binding pocket 
and a C-terminal aldehyde for attachment to the active site cysteine were prepared by 
members of the cataract group. The N-terminal diazo groups of (E)-3.36a,c and (E)-3.37a 
were photochemically isomerized to give an alternative photostationary state in which the 
(Z)-isomer predominates. These mixtures, enriched in either the (E)-or (Z)-isomer, were 
assayed against m-calpain to further explore and define the P3 binding pocket. This new class 
of N-terminal group was extended to more water soluble triazene-dipeptide aldehydes 
3.38a,b, with 3.38a being assayed in lens culture to determine its ability to arrest the 
development of calpain-induced cataract. 
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Samples of the dipeptidic aldehydes 3.36a-d, 3.37a,b, and 3.38a,b, consisting of 
predominantly the (E)-isomer, were assayed against m-calpain using a fluorescence-based 
assay
12
 to determine in vitro potency, and the results are summarized in Table 3.5. The initial 
(E)/(Z)-isomer mixtures for 3.36a, 3.36c, and 3.37a were irradiated with ultraviolet light (500 
W mercury arc lamp through a UV filter with a narrow wavelength band centered at 340 nm) 
to give samples enriched in the (Z)-isomer [1:4.3, 1:4, and 1:3.7 mixture of (E)- and (Z)-
isomers, respectively, Table 3.5]. These new photostationary states of 3.36a, 3.36c, and 
3.37a (Table 3.5) were also assayed against m-calpain to further assess the available space in 
the S3 binding pocket, to which the diazobenzene groups purportedly bind as revealed by 
molecular modeling.
16
 The computational methods can be found under Protocol 6 in the 
Appendix. 
 
Table 3.5: Inhibition of m-Calpain by Different Photostationary States of the Diazo and Triazene-dipeptide 
Aldehydes 3.36a-d, 3.37a,b, and 3.38a,b 
 
   IC50 
Compound
a E/Z Compound Structure  (nM) m-calpain 
3.36a 4.8:1 
 
45 
3.36a 
(irradiated) 
1:4.3 
 
175 
3.36b 5.4:1 
 
35 
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3.36c 4.9:1 
 
75 
3.36c 
(irradiated) 
1:4 
 
105 
3.36d 5.4:1 
 
170 
3.37a 3.3:1 
 
40 
3.37a 
(irradiated) 
1.3:7 
 
100 
3.37b 7:1 
 
90 
3.38a 23:1 
 
90 
3.38b 233:1 
 
420 
 
a
 The major isomer before irradiation is assigned as the thermodynamically more stable (E)-isomer, based on 
literature precedence.12
 b
 Substitution position. 
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Figure 3.17: Picture of docked compound 3.37a in the (E)-enriched photostationary state overlayed with 3.37a 
in the (Z)-enriched photostationary state. 
 
The most active dipeptidic aldehyde mixture 3.36b had an IC50 value of 35 nM, which is 
significantly more potent than the calpain inhibitor SJA6017 3.10 (IC50 ) 80 nM in our 
assay).
17
 The inhibitor mixtures 3.36a (45 nM), 3.36c (75 nM), 3.37a (40 nM), and 3.38a (40 
nM) are also particularly potent. Of all the sample mixtures, only 3.36d (170 nM) and 3.38b 
(420 nM) are less potent than 3.10 (Table 3.5). 
 
The S1 pocket can accommodate both Leu and Phe at the P1 position; however, there 
does seem to be some preference for Leu at this position; compare assay results for 3.36a,b, 
3.36c,d, and 3.37a,b (Table 3.5). With regard to potency, there does not seem to be any 
consistent preference for an amide or sulfonamide linker; compare the activity of 8a-10a and 
3.36b-3.37b (Table 3.5). Inhibitors with 4-substitution of the N-terminal aryl group (3.36a,b) 
are more potent than those with 3-substitution (3.36c,d). 
 
The triazenes 3.38a,b are less potent than the diazo compounds 3.36a-d and 3.37a,b. The 
planar and extended aromatic nature of the (E)-diazo group of 3.36a,b and 3.37a,b appears to 
allow for better interaction with this flat S3 binding pocket, when compared to the 
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corresponding triazenes 3.38a,b. This is consistent with the lower potency of the triazenes 
3.38a,b (see Table 3.5). 
 
Induced fit modeling
18
 shows each µ-calpain docked inhibitor adopts a β-strand 
conformation.
19
 The poses of (E)-3.36a, (E)-3.36b, (E)-3.36c, (Z)-3.36c, (E)-3.37a, (E)-
3.38a, and (E)-3.38b docked with a µ-calpain construct are shown in Figure 3.18a. This is 
consistent with published crystal structures of µ-calpain with inhibitor bound.
5, 6, 20
 The 
docked poses for (Z)-3.36a, (E)-3.36d, (Z)-3.37a, and (E)-3.37b (not shown in Figure 3.18a) 
also revealed a β-strand conformation of the inhibitor but with only two of the three hydrogen 
bonds apparent. The model also predicts the aldehyde group in all cases to be in close 
proximity to the active site cysteine, as required for mechanism-based inhibition. 
 
 
Figure 3.18: (a) β-Strand backbone conformations of (E)-3.36a, (E)-3.36b, (E)-3.36c, (Z)-3.36c, (E)-3.37a, (E)-
3.38a, and (E)-3.38b, resulting from the inducedfit modeling. (b) Induced-fit overlay of the S3 subsite of calpain 
with docked (E)-3.37a (blue) and (Z)-3.37a (red). 
 
 
The inhibitory activity of the isomeric mixtures of 3.36a, 3.36c, and 3.37a decreased, on 
irradiation, by a factor of 3.9, 1.4, and 2.5, respectively. For example, the inhibitory activity 
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of 3.36a decreased from 45 nM for a sample containing 83% (E)-isomer to 175 nM for a 
mixture containing 4-fold less of the (E)-isomer (i.e., 19% (E)-isomer with 81% (Z)-isomer), 
see Table 3.5. The (E)-isomers are significantly more active in each case,
21
 reflecting a better 
fit in the S3 binding pocket associated with their geometry and dipole moment. In fact, 
modeling suggests that the diazo group of (Z)-3.37a, unlike (E)-3.37a, appears not to bind in 
the S3 binding pocket, but rather interacts with a hydrophobic patch on the mobile loop that 
defines the calpain active site (Figure 3.18b). This is consistent with the observed higher 
potency of the photostationary state enriched in the (E)-isomer (see Table 3.5 and previous 
discussion). A photoisomerizable N-terminal diazobenzene of this type provides both a useful 
probe for mapping the size and geometry of the S3 binding domain and evidence for 
enhancing interactions between this pocket and a P3 aryl group of an inhibitor. An empirical 
preference for the interaction of an aryl group with S3 has been previously suggested,
5
 and 
our study supports this observation. 
 
The in vivo potential of these highly potent inhibitors was next determined by assessing 
their ability to retard calpain induced cell damage in sheep lenses cultured in Eagle‟s minimal 
essential medium. Inhibitor 3.38a was chosen for study because of its superior water 
solubility, as compared to 3.36a-d and 3.37a,b, and also its high in vitro potency, as 
compared to the other triazene 3.38b. The triazene moiety of 3.38a is also amenable to salt 
formation that makes it attractive as a potential drug candidate. 
 
Inhibitor 3.38a (0.8 µM) was added to one lens from each pair of sheep lenses in culture 
media by our Lincoln collaborators. Two hours later calcium was added to all lenses to 
activate the constituent calpains and hence induce cataract formation. After 24 h, all lenses 
were photographed and the opacity graded; see Figure 3.19 for representative examples. 
Lenses treated with calcium only (e.g., lens 1 in Figure 3.19) clearly showed the opacity 
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associated with cataract formation; however, lenses treated with calcium in the presence of 
3.38a (e.g., lens 2) remained essentially clear, as revealed by the reference grid placed behind 
each lens. The loss of transparency was significantly reduced by 3.38a (p < 0.005) in a paired 
t-test. It would thus appear that this class of inhibitor, with an N-terminal group capable of 
binding deep into the S3 binding pocket, is active in vitro and in vivo (lens assay) and is thus 
of interest as a potential drug candidate. 
 
 
Figure 3.19: Calcium-induced cataract in sheep lenses. The scores represent the average result using three lens 
pairs. Opacification scores of 100 = full opacity, whereas a score of 1 = clear and transparent. 
 
3.5 Conclusion 
 
Known inhibitors of calpain were examined in detail to determine what attributes they 
possessed that determine them to be good inhibitors. Most of the inhibitors in the literature 
are peptide based and are known to bind in a β-strand conformation. The known natural 
inhibitors such as leupeptin were found by researchers to be poor drug candidates as they 
were non-selective and had low membrane permeability. Other researchers discovered that 
this could be overcome by the addition of N-terminal capping groups, a fact that lead our 
team to research further. 
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The Glide model was tested to see if it was a viable model for docking studies. The 
compounds of Inoue et al
11
 were deemed to be ideal for this as they are a series of 
compounds with a basic di-peptide frame that had different substituents, side chains and 
chirality. They also have IC50 data against rat µ-calpain that can be compared with the 
docking data. The docking data obtained from the study of the eighteen compounds was 
shown to be consistent with the IC50 data. It was shown that compounds such as 3.10 with 
good inhibition of calpain docked into the model with all the required parameters to suggest it 
was a good inhibitor. Conversely, compounds that had poor IC50‟s such as 3.22 showed that 
they could not dock in the required manner by having a poor Glide score, less than the 
required three H-bonds, a warhead further than 5Å from Cys115, and/or an excessive number 
of „ugly‟ internal contacts. The important point here is that docking of the compounds into 
the Glide model generated data that predicted, with reasonable accuracy, the likelihood that a 
compound would inhibit calpain in vitro. Now that we had a working viable model we could 
proceed with docking of our in house compounds and making a contribution as to what 
compounds were likely to be inhibitors and therefore worthy of synthesis. 
 
Next, a series of N-heterocyclic compounds based on the lead compound 3.10 were 
suggested as possible candidates by our synthetic chemists following from the work of other 
groups showing that addition of N-terminal capping groups could improve selectivity and 
membrane permeability.  Specifically we have investigated the potential of different N-
terminal capping groups to interact with the P3 position in the enzyme. 
  
The Glide docking studies showed that most of the compounds (3.26-3.35) could dock in 
the required manner. However, 3.26 and 3.33 docked into the model in a previously unseen 
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pose. They still had all the requirements of good inhibitors but the three essential H-bonds 
were in a different position on the ligand. Compound 3.34 did not dock with Glide but did 
dock appropriately when the InducedFit Protocol was implemented.  
 
Based on their „unique‟ docking poses, compounds 3.26 and 3.33 were synthesized and 
tested against both µ- and m-calpain along with all the other N-heterocyclic compounds. All 
the compounds were shown to be good or very good inhibitors of µ- and m-calpain. 
Compound 3.26 turned out to be the most potent against m-calpain (IC50 of 25 nM) and was 
ten times more selective for m-calpain over µ-calpain and compound 3.33 was the most 
potent against m-calpain (IC50 of 150 nM) but was not selective. Docking had predicted that 
most of these compounds would be good inhibitors of calpain and that the „unique‟ docking 
of compounds 3.26 and 3.33 suggested that these compounds were worthy candidates for 
synthesis. 
 
The series of diazo- and triazene-dipeptide aldehydes 3.36a-d, 3.37a,b, 3.38a,b prepared 
predominantly as the (E)- isomers are all highly potent against m-calpain, with the most 
potent 3.36b [5.4(E)/1(Z)] having an IC50 value of 35 nM. Photoisomerism of the diazo 
inhibitors 3.36a-c and 3.37a gave samples enriched in the (Z)-isomer that proved to be 
significantly less active. SAR data suggests that an N-terminal diazo group (3.36a-d) is 
favoured over a triazene (3.38a,b). Furthermore 4-substitution of the N-terminal diazo group 
(3.36a,b) is favoured over 3-substitution (3.36c,d). The triazene of 3.38a imparts improved 
water solubility for in vivo studies and was shown to arrest the development of calpain-
induced cataract formation in sheep lens culture. 
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 Molecular modeling predicts that these compounds all bind in an extended β-strand 
conformation, as defined by three key hydrogen bonds to Gly208 and Gly271. This is 
consistent with published crystal structures of µ-calpain with the inhibitor bound 
demonstrating the validity of the modelling methodology.
5,6,20
 The reactive carbonyl in each 
case is located in close proximity to the active site cysteine, as would be required for 
mechanism-based inhibition. As a consequence, the N-terminal group of the (E)-diazo 
dipeptide aldehydes 3.36a-d and 3.37a,b extends deep into the S3 binding pocket. 
 
A calpain inhibitor, the activity of which can be influenced by irradiation, offers some 
potential as a means to actively control cataracts and this is a first step toward such a goal. 
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4 Molecular modelling of cyclic inhibitors 
 
4.1 Introduction 
 
Cyclic inhibitors can have an advantage over an acyclic counterpart. Cyclization can 
preorganize functionality on a ligand to dictate conformations that the target enzyme readily 
recognizes and in so doing can lower the entropic barrier for inhibitor-enzyme complex 
formation.
1-5
 Acyclic inhibitors, such as small peptide like compounds, contain a number of 
rotatable bonds. The more rotatable bonds a ligand has the more conformationally flexible the 
ligand is likely to be, and because a ligand binds to an enzyme in a specific conformation it 
can be desirable to minimise this entropic flexibility. As we have already discussed native 
polypeptide substrates of protease enzymes are often folded into well defined conformations 
which are almost exclusively of the β-strand variety.6-8 Locking functionality of a ligand into 
such a conformation can be achieved by cyclization which reduces conformational flexibility, 
with a consequent increase in binding affinity.
1
  
 
4.2 First generation cyclic analogues: modelling studies of 8-
membered cyclic analogues of SJA-6017 
 
One of the most potent inhibitors discussed so far is N-(4-fluorophenylsulfonyl)-L-valyl-
L-leucinal (SJA-6017) (compound 3.10 in Figure 4.1).
9, 10
 This compound displays potent 
inhibition of calcium activated m-calpain (IC50 = 80 nM)
9
 and has been shown to be effective 
against selenite induced cataract formation in rats
11
 and in cataractic porcine lenses.
12
 In 
addition it has low toxicity, it is specific for cysteine proteases, but suffers from low 
4   Molecular modeling of cyclic inhibitors 
 
 85 
permeability into the cell and it binds indiscriminately and readily to proteins. In vitro studies 
with human plasma have shown that 95.4% of 3.10 at a concentration of 10 M is bound to 
the plasma proteins.
10
 Therefore, it is necessary to make structural modifications to this 
compound without compromising its potency or specificity. 
 
Our first studies, before coordinates of the µ-capain construct were known, focused on 
the cyclic analogues 4.1 of 3.10 with the leucinal and valyl side chains modified and linked to 
form an 8-membered ring.
13-15
 This structural modification restricts the conformational 
flexibility of the amide linkage. The non natural environment of the amide linkage will alter 
its proteolytic stability as proteases may be less able to recognize it. Furthermore, the 
modification will change the hydrophilicity and thereby the ability to cross membranes, a 
major problem of the lead compound 3.10. The restricted conformational space brought about 
by the 8-membered ring may also decrease the unspecific binding to other proteins. The 
results of the activity tests of 4.1, having limited conformational flexibility, is intended to 
allow us to investigate further the requirements for molecular recognition in the active site of 
calpain. In general, most proteases are considered to preferably cleave amide bonds that are 
part of a β-strand secondary conformation.2, 6 The synthetic route for these compounds 
follows that by Creighton et al.
13
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Figure 4.1: The known calpain inhibitor SJA0617 (3.10) resembles the cyclic analogue 4.1 when adopting a cis 
peptide bond conformation. 
 
The first generation cyclic analogues of SJA6017 (3.10) that were prepared in our group 
were therefore synthesized before we had suitable models of the enzyme. The leucinal and 
valyl side chains were modified and linked to form an eight-membered ring thereby 
restricting conformational flexibility of the intramolecular amide bond. It was hoped that 
such a cyclic analogue would help overcome problems of SJA6017 and be a drug candidate 
without compromising potency or specificity. The problems associated with SJA6017 include 
being too hydrophilic to cross membranes (low cell permeability) and binding 
indiscriminately and readily to other proteins resulting in low bioavailability.
10
 
 
Compounds 4.3-4.8 (Figure 4.2) were tested for calpain inhibition and shown to be 
inactive and now, with appropriate enzyme model coordinates, subsequent modelling, which 
we now report, demonstrated why they were inactive. The fact that the equilibrium mixture of 
diols 4.7 and 4.8 and aldehydes 4.2l and 4.2u were inactive is particularly significant as it 
showed the importance of the β-strand in calpain inhibitor design.  
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Modeling studies using MacroModel
16
 were used to establish the global minima and 
ensemble of low energy conformations of the compounds 4.3-4.8, 4.2l and 4.2u in simulated 
water using Protocol 3 in the Appendix. The ensembles of generated structures were 
clustered using the program X-cluster
17
 and the clusters within 12 kJ/mol window of the 
global minima were analysed. The clusters represent the backbone motifs for these cyclic 
conformationally restricted structures. It is worth noting that the unlike diastereomers 4.4, 
4.6, 4.8 and 4.2u contain one amino acid of unnatural configuration. Also none of the 
diastereomers can adopt typical peptide secondary structural motifs such as α-helical, β-
strand or β-turns. The global minima conformations for 4.3 and 4.4 are shown in Figure 4.3 
and Figure 4.4 as examples of major backbone conformations of like and unlike 
diastereomers. The Boltzmann weighted calculations of the ensembles of structures gave for 
each diastereomer the potential energy, distances between the chiral methine protons, the 
number of hydrogen bonds, and provided for the determination of the ratio of the number of 
hydrogen bonds for the diastereomers (Table 4.1).  
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Figure 4.2 Compounds modelled and tested: 
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Figure 4.3: Stereo view of the global minimum conformation of 4.3.  
 
 
 
Figure 4.4: Stereo view of the global minimum conformation of 4.4. 
 
 
Table 4.1: Modelling data for the lowest energy conformation of 4.2l, 4.2u and 4.3-4.8.  
 
 
 4.3 4.4 4.5 4.6 4.7 4.8 4.2 l 4.2 u 
a 96.5 104.4 -3.5 7.6 -130.4 -129.6 -12.9 -5.8 
b 7.9  11.1  0.8  7.1  
c 2.3 4.0 2.1 3.9 2.0 3.9 2.1 3.7 
d 2.3 4.0 2.1 3.9 2.1 3.8 2.1 3.8 
e 2.0 1.0 2.0 1.0 2.0 2.0 2.0 0.9 
f 1.7:1  2.0:1  0.9:1  1.7:1  
g 2.1:1  2.0:1  1.0:1  2.1:1  
 
a: Boltzmann weighted average ensemble energy [kJ/mol]; b: energy difference between the ensembles of like 
and unlike diastereomers [kJ/mol]; c: average distance between the chiral methine protons of the ensembles [Å]; 
d: Boltzmann weighted distance between the chiral methine protons of the ensembles [Å]; e: Boltzmann 
weighted average number of H-bonds per conformer in the ensembles; f: average ratio of the number of H-bonds 
of the like and unlike diastereomers; g: Boltzmann weighted average of the like:unlike ratio of H-bonds.
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Of the hydrated aldehydes 4.7 and 4.8 the major diastereomer is 4.7, which is calculated 
to be the more thermodynamically favoured, but by only 0.8 kJ/mol. The higher 
thermodynamic stability of the like diastereomers 4.3, 4.5, and 4.2l is explained by the 
modeling results (see Table 4.1). The Boltzmann weighted energy of the ensemble of 
conformers of the like diastereomers is in all cases lower for the corresponding unlike 
diastereomers 4.4, 4.6, and 4.2u. This observation correlates with the higher average and the 
higher Boltzmann weighted average number of internal hydrogen bonds for the like 
diastereomers (see Table 4.1).  
 
It is notable that for the hydrated aldehydes 4.7 and 4.8 the energy difference is 
significantly lower than between all the other pairs of diastereomers. Also the difference in 
the average and the Boltzmann weighted average number of internal hydrogen bonds between 
the diastereomers is small (see Table 4.1). This supports the importance of intramolecular 
hydrogen bonding in differentiating the energy between the diastereomers. 
 
The preferential formation of 4.7 over 4.8 can be explained most convincingly by the 
energy difference of the precursors 4.2l and 4.2u that differ more in energy than the diols. 
 
The relative configuration of the diastereomers was determined from molecular 
modelling and NMR studies where the distances between the methine protons correlate with 
NOE measurements.  For example an appropriately weighted distance of 2.28 Å between the 
chiral methine protons of 4.3 (Figure 4.3) is consistent with the observed NOE for the like 
diastereomer. While for the unlike diastereomer 4.4 (Figure 4.4) the weighted distance was 
3.96 Å and no NOE could be detected. Similar weighted distances and NOE observations of 
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the chiral methine protons were apparent for all like/unlike pairs, confirming the relative 
stereochemistry of the chiral carbons. 
 
The absence of calpain inhibition by all of the 8-membered cyclic compounds, but 
especially by diols 4.7 and 4.8, which will be in equilibrium with the aldehydes 4.2l and 4.2u, 
is significant. The compounds are not able to adopt the typical peptide secondary structural 
motifs β-strand, β-turns, or α-helix. Figure 4.5 shows compound 3.10, which can form the 
„zigzag‟ pattern of a β-strand along the backbone, superimposed with compound 4.2u, which 
cannot form this type of conformation. This is because the 8-membered ring forces the 
backbone of the dipeptide to form a cis conformation at the peptide bond rather than the trans 
conformation required for β-strand formation. These results are in accordance with the 
assumption that a β-strand structure of a compound is required for molecular recognition by 
calpain as shown for many known protease inhibitors and substrates.
2, 6
 
 
Figure 4.5. The lowest energy conformer of SJA-6017 (3.10) (black) showing a β-strand conformation 
superimposed with compound 4.2u, which inherently cannot form a β-strand. 
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In summary, a series of conformationally restricted 8-membered cyclic analogues of 3.10 
were synthesized, tested, and modelled. The higher calculated thermodynamic stability of the 
like diastereomers 4.3, 4.5, and 4.2l correlates with the prevalence of internal hydrogen 
bonds. The compounds are not able to adopt typical peptide secondary structural motifs. No 
inhibition of any of the compounds in this study, especially by diols 4.7 and 4.8, which will 
be in equilibrium with the aldehydes 4.2l and 4.2u, could be shown. These results are in 
agreement with the putative importance of a β-strand structure for inhibitors and substrates of 
calpain, a structural feature exhibited for several known protease inhibitors. This gives further 
information on the requirements for molecular recognition in the active site of calpain. 
 
 
4.3 Second generation cyclic analogues: modelling studies of ca 
17 membered macrocyclic ring analogues of SJA-6017 
 
We then attempted to design small conformationally constrained macromolecules that 
form a β-strand type conformation so that the amino acid segment of the molecule positions 
functional groups appropriately for binding with the calpain enzyme. This second generation 
of cyclic inhibitors have been based on Fairlie‟s6 analysis of the importance of  a β-strand for 
bioactivty. He reported in an important publication that nearly all known substrates of  known 
proteases bind in an extended β-strand conformation.2 The aim of my work has been directed 
to constraining an inhibitor in such a bioactive conformation, thus, lowering the entropic 
barrier for binding of the inhibitor to the enzyme.  
 
Fairlie
6
 reported that incorporating a tripeptide into a ca 17 membered ring favours the 
tripeptide in an extended β-strand conformation.2, 6-8 To investigate if we could 
conformationally constrain our lead compound (SJA6017) as a macrocycle, in a β-strand, a 
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library of possible candidates (structures) were devised by Dr Steve Aitken, then a PhD 
student. For inclusion of a candidate in the virtual library we first required that a reasonable 
synthetic route be available. The virtual library is constructed from an 18x16 grid matrix 
shown in Table 4.2 to yield 288 possible tripeptide macrocyclic structures. The proposed 
synthetic route to generating each macrocycle is as follows: An N-BOC-allyl-amino acid with 
an olefin in the side chain (left columns Table 4.2) is coupled with an allyl-amino acid 
methyl ester also with an olefin in the side chain (right columns Table 4.2) to yield the 
corresponding diene. Ring closing metathesis can be used to generate the macrocycles, a 
method proven by Dr Sigeru Miyamoto‟s study of compounds 4.2u, 4.2l, and 4.3-4.8.  
 
These 288 possible core structures could be modified to give different warheads and 
protecting groups. For the initial conformational search the warhead for each of the 288 
structures was an aldehyde and the protecting group was 4-fluorobenzyl sulphonamide. For 
example, N-BOC-allyl-amino acid 1 coupled with allyl-amino acid methyl ester A would 
give structure X (Figure 4.5). If X was modified to be an aldehyde protected with 4-
fluorobenzyl sulfonamide it would give structure A1 in Figure 4.5.  A conformational search 
of each structure generated ensembles of the low energy conformers described in Protocol 3 
in the Appendix. 
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Table 4.2 Acids 1-18 coupled with esters A-P and closed with ring closing metathesis to give in silico library of 
288 macrocyclic tripeptides. These were modified in silico to give the equivalent 4-fluorobenzyl sulphonamide 
protected aldehydes to give compounds labelled A1, A2, A3...P16, P17, P18. 
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Figure 4.5 X is an example of the structure when acid 1 is coupled with ester A and closed with ring closing 
metathesis. A1 is the 4-fluorobenzyl sulphonamide protected aldehyde of X used for the conformational search. 
 
 
4   Molecular modeling of cyclic inhibitors 
 
 94 
4.3.1 Docking of macrocyclic analogues of SJA6017 using Glide 
 
We had not performed any docking experiments of the macrocycles before and did not 
know if the Glide model would accommodate these comparatively large compounds 
(compared with the smaller di-peptides we had previously docked). In order to test if the 
Glide model would work we took the first ten compounds, A1-A4, B1-B4, C1 and C2 
(Figure 4.6), in the 288 compound library and docked them using Glide with the parameters 
shown in Protocol 4 in the Appendix. These ten compounds display macrocyclic ring sizes 
from 14-18 which gave a range of sizes to test.  
 
The following is Glide docking data of ten selected compounds from the matrix: The 
lowest energy conformer of compounds A1-A4, B1-B4, C1 and C2 (Figure 4.6) were docked 
into the µ-calpain construct (1KXR) model using Glide (Protocol 4 in the Appendix). 
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Figure 4.6; Chemdraw structures of compounds A1-A4, B1-B4, C1 and C2. 
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Compounds A1, A4, and C1 docked into the active site with the essential criteria of the 
three H-bonds displaying a β-strand, close electrophile-nucleophile proximity, and low Glide 
and E-model scores (see Table 4.3 and Figure 4.7).  The capping group of each is oriented so 
that it sits over Gly 208.  
 
Compound A1 has been subsequently synthesized and tested in house and has a 
moderate IC50 of 3710nM against ovine m-calpain. Compounds A1 and A4 both have some 
„ugly‟ internal contacts, a possible reflection on compound A1‟s less than flattering IC50. 
„Ugly‟ internal contacts mean that the compound has had to be put in a slightly unfavourable 
conformation in order to fit into the active site. In a real system, movement in the active site, 
which may or may not be better for enzyme-inhibitor binding, could allow the compound to 
bind in a slightly more favourable conformation. 
 
Table 4.3: Docking data for best pose
a
 (out of possible 10) and inhibitory concentrations (IC50) for compounds 
A1-A4, B1-B4, C1 and C2 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
m-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
A1 -5.1 -54.9 3 4.4 280 22 2 3710 
A2 -4.3 -56.4 0 >5 295 26 0  
A3 -4.7 -40.8 0 >5 282 13 2  
A4 -4.3 -48.8 3 4.7 259 16 3  
B1 -5.4 -43.7 0 >5 296 15 1 280 
B2 -5.9 -49.4 0 >5 299 23 1  
B3 -4.4 -42.9 0 >5 284 11 1  
B4 -4.4 -43.8 0 >5 287 16 0  
C1 -4.4 -52.2 3 4.2 327 16 0  
C2 -5.5 -60.3 0 >5 330 18 0  
 
a
  Best pose chosen by criteria in order of importance; 1 - presence of three essential hydrogen bonds, 2 - 
warhead within 5Å of nucleophilic Cys115, 3 - low Glide score/emodel score, 4 - lowest number of internal 
ugly contacts. 
 
b
  GlideScore
18
 is a scoring function based on ChemScore
19
 which is designed to estimate free energy of binding 
for protein–ligand complex. The function uses simple contact terms to estimate lipophilic and metal–ligand 
binding contributions, a simple explicit form for hydrogen bonds and a term which penalises flexibility. 
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c
  Emodel
18
 is a model energy score that combines energy grid score, binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy. 
 
 
Figure 4.7: Best docked pose of compound A1 (left) compound A4 (middle), and compound C1 (right). All 
docked with Glide into µ-calpain model. 
 
The other seven compounds in this docking experiment did not dock into the enzyme 
model with the proposed essential criteria as can be seen in Figure 4.8 (showing only docked 
poses of A2, A3, and B3) and Table 4.3. It was also noticed that some of these docked 
compounds were not in a β-strand conformation. Of these seven compounds only A2 was 
found to have its starting conformation in a β-strand. 
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Figure 4.8: Best docked pose of compound A2 (left), compound A3 (middle), and compound B3 (right). All 
docked with Glide into µ-calpain model. 
 
Compound A2 displays a β-strand conformation but none of the docked poses of A2 
showed that the compound could form the three essential H-bonds. A2 differs from A1 only 
at the P2 position where a phenylalanine replaces a valine. The bulkier phenylalanine side 
chain of compound A2 may not fit into the deep hydrophobic pocket of the enzyme model 
where P2 side chains are known to bind.
20-22
 
 
After this initial docking experiment was performed and it was noticed that some of the 
docked compounds were not in a β-strand and a closer look at the ensemble of low energy 
macrocycles was made. Many of the low energy conformers of the 288 compounds were 
found to not be in the intended β-strand and were in fact displaying a type of turn, and in a 
few cases they were displaying a conformation in between a β-strand and a γ-turn. I have 
called this structure a 'twist' conformer. The turns are actually a form of a γ-turn which is a 
rare conformational feature in natural peptides. Examples of a macrocycle in a β-strand and a 
turn are shown in Figure 4.9.  
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Figure 4.9. Macrocycle A3 in a low energy β-strand conformation (grey carbons) superimposed with a low 
energy conformation of A3 in a turn type conformation (green carbons). 
 
The ensembles of low energy conformers of the six structures (compounds A3, B1, B2, 
B3, B4, and C2) that did not have a β-strand conformation as the lowest energy conformer 
(used as the starting conformer for initial docking) were examined to determine (see 
discussion below on appropriate parameters to describe a β-strand) the lowest energy 
conformer that displayed a β-strand, if any. These low energy conformers that displayed a β-
strand were then docked with the same parameters as before to determine if they could bind 
into the active site with the essential criteria when their starting conformer was in a β-strand. 
 
Compounds B1, B2, and B3 when in a β-strand starting conformation were shown to 
dock into the active site with all or most of the essential criteria intact (Table 4.4). 
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Table 4.4: Docking data for best pose
a
 (out of possible 10) and inhibitory concentrations (IC50) for compounds 
B1, B2, and B3 when starting conformer was the lowest energy conformer in a β-strand. 
 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
m-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
B1 -4.4 -52.1 3 3.5 284 19 4 280 
B2 -5.5 -60.1 2 3.9 310 19 1  
B3 -6.6 -49.3 3 3.5 254 11 0  
 
a
  Best pose chosen by criteria in order of importance; 1 - presence of three essential hydrogen bonds, 2 - 
warhead within 5Å of nucleophilic Cys115, 3 - low Glide score/emodel score, 4 - lowest number of internal 
ugly contacts. 
 
b
  GlideScore
18
 is a scoring function based on ChemScore
19
 which is designed to estimate free energy of binding 
for protein–ligand complex. The function uses simple contact terms to estimate lipophilic and metal–ligand 
binding contributions, a simple explicit form for hydrogen bonds and a term which penalises flexibility. 
 
c
  Emodel
18
 is a model energy score that combines energy grid score, binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy. 
 
When compound B1 was docked, using the lowest energy conformer in a β-strand, into 
the enzyme model all the essential criteria was displayed (Figure 4.10 left), however, four 
„ugly‟ internal contacts were identified. 
 
Figure 4.10: Best docked pose of compound B1 (left), compound B2 (middle), and compound B3 (right). All 
docked with Glide into µ-calpain model. 
 
 
Compound B2 docked using Glide with all essential elements of the required criteria 
except only two of the three essential H-bonds were observed (Figure 4.10 middle). The third 
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H-bond was absent but the atoms usually involved in this H-bond were relatively close to 
being able to form such a bond. B2, like A2, has a phenylalanine in the P2 position which 
requires more space in the S2 subsite due to being bulkier than the valine side chain of 
compounds like B1. This fact may be why B2 is docked somewhat higher out of the pocket 
which consequently causes the backbone NH to be further away from the backbone oxygen 
of Gly208 and so no H-bond was observed. It also had one „ugly‟ internal contact. 
 
Compound B3 was shown to dock in the required manner when the lowest energy 
conformer in a β-strand was used as the starting conformer in the docking experiment (Table 
4.4 and Figure 4.10 right). It had a low Glide score of -6.6 and showed no „ugly‟ internal 
contacts. 
 
In contrast, compounds A3, B4, and C2 did not dock in the required manner even when 
docking was performed using their lowest energy conformers in a β-strand. 
 
Overall, the Glide docking study showed that compounds A1, A4, B1, B3, and C1 could 
dock with Glide into the active site of the Glide calpain model with the three critical H-bonds 
intact, with a warhead to nucleophile distance of less than 5Å, and with low Glide and 
Emodel scores. This occurred only when the lowest energy conformer in a β-strand was used 
as the starting conformer in Glide. Of these five compounds only B3 and C1 had no „ugly‟ 
internal contacts. The other three compounds in this group had docking poses with a low 
number of „ugly‟ internal contacts. 
The rigidity of the Glide enzyme model (a limitation of Glide docking) was hypothesized 
to be a possible factor as to why some of the compounds with larger P2 side chains, namely 
compounds A2, B2, and C2, could not fit into the active site in the appropriate way. It was 
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also possible that the side chain of Lys347 was hindering the docking of some compounds as 
its proximity was in the region where the ligand capping groups could possibly dock. The 
long side chain of Lys347 has the ability to reposition itself to form H-bonds to atoms of the 
ligand capping groups.  
 
For the above reasons it was deemed necessary and best to use Schrodinger‟s InducedFit 
Protocol for subsequent docking. The InducedFit Protocol uses a program script that 
combines the docking program Glide with the protein structure prediction suite called Prime 
with the aim of simulating movement of the active site upon ligand binding. It was hoped that 
movement of the active site would also help some ligands „relax‟ so that some of the „ugly‟ 
internal contacts seen in the pure Glide docking would not form. The side chain of Lys347 
could also be temporarily removed during the initial docking phase of the InducedFit 
Protocol to allow an easier fit for the macrocycles and subsequent movement of the flexible 
side chain of Lys347. 
 
4.3.2  Docking of macrocyclic analogues of SJA6017 using InducedFit 
 
The compounds A1-A4, B1-B4, C1 and C2 (Figure 4.6) used in the previous section for 
Glide docking were subsequently docked into the enzyme model using the InducedFit 
Protocol (Protocol 5 in the Appendix). 
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Table 4.5: Docking data for best pose
a
 (out of possible 20) and inhibitory concentrations (IC50) for compounds 
A1-A4, B1-B4, C1 and C2 when InducedFit docking was used. 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
m-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
A1 -7.4 -84.0 3 4.2 217 17 0 3710 
A2 -7.4 -67.8 2 >5 274 26 0  
A3 -6.7 -77.3 3 3.8 254 8 0  
A4 -8.8 -77.3 3 4.9 258 5 0  
B1 -8.1 -53.5 3 3.9 287 16 1 280 
B2 -7.0 -88.7 0 >5 287 21 0  
B3 -7.9 -69.0 3 4.4 261 10 1  
B4 -7.6 -81.6 0 >5 292 4 0  
C1 -6.0 -77.2 0 >5 300 18 0  
C2 -6.4 -78.6 3 4.1 307 31 6  
 
a
  Best pose chosen by criteria in order of importance; 1 - presence of three essential hydrogen bonds, 2 - 
warhead within 5Å of nucleophilic Cys115, 3 - low Glide score/emodel score, 4 - lowest number of internal 
ugly contacts. 
 
b
  GlideScore
18
 is a scoring function based on ChemScore
19
 which is designed to estimate free energy of binding 
for protein–ligand complex. The function uses simple contact terms to estimate lipophilic and metal–ligand 
binding contributions, a simple explicit form for hydrogen bonds and a term which penalises flexibility. 
 
c
  Emodel
18
 is a model energy score that combines energy grid score, binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy. 
 
Compound A1 docks into the calpain InducedFit model with appropriate criteria met, 
namely the three essential H-bonds, a warhead-nucleophile distance of <5Å, and low Glide 
and Emodel scores (Table 4.5). It also showed no „Ugly” internal contacts. In addition to the 
three essential H-bonds observed (left Figure 4.11) a fourth H-bond occurs between the 
aldehyde oxygen and Cys115. Lys347 has moved down towards the active site pocket to 
accommodate the ligand‟s capping group which has the 4-fluoro atom pointing towards the 
side chain of Trp224. 
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Figure 4.11; Best docked pose of compound A1 (left) and compound A2 (right). All docked with the Induced 
Fit protocol into the InducedFit µ-calpain model 
 
In parallel with the Glide docking study, compound A2 does not bind in the required 
mode when the InducedFit protocol was employed (Table 4.5 and right Figure 4.11). Again 
this underlines that the phenylalanine P2 side chain hinders docking due to its bulk not being 
able to fit into the S2 subsite. 
 
Compounds A3, A4, and B1 all show good InducedFit docking parameters (Table 4.5). 
They all have additional H-bonds present in their respective best docked pose. Compound A3 
has two extra H-bonds (Figure 4.12), one between the amide nitrogen at the capping group 
end and the side chain of Asn253, and another involving the aldehyde warhead oxygen of the 
ligand and the SH of Cys115.  
 
Compound A3 did not dock appropriately when docked using Glide, even from a β-
strand starting conformation. The InducedFit protocol allows a small amount of movement in 
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the enzyme to accommodate the ligand so that it can bind in a manner akin to a „good‟ 
inhibitor of calpain. 
 
Compound A4 has additional H-bonds, both from one of the oxygens of the sulfonyl 
capping group to the side chain of Asn253 and side chain of Ser251. It has an excellent Glide 
score of -8.8.  
 
 
Figure 4.12: Best docked pose of compound A3 (left), compound A4 (middle), and compound B1 (right). All 
docked with the Induced Fit protocol into the InducedFit µ-calpain model 
 
Compound B1 has an additional H-bond from the NH group at the capping group end to 
the side chain sulphur of Cys209 (Figure 4.12). It has an excellent Glide score of -8.1 and a 
moderately good IC50 of 280 nM against m-calpain. It has only one „ugly‟ internal contact. 
This compound failed to dock in the required manner with the Glide docking protocol. This 
could be due to the macrocycle ring of B1 being larger than the analogous compound A1 by 
one carbon bond. The InducedFit protocol allows enough movement in the enzyme model to 
allow B1 to dock appropriately for inhibition. 
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Figure 4.13: Best docked pose of compound B2 (left), compound B3 (middle), and compound B4 (right). All 
docked with the Induced Fit protocol into the InducedFit µ-calpain model 
 
The InducedFit protocol failed to allow compound B2 to dock into the model with the 
appropriate criteria (Table 4.5 and left Figure 4.13). This was also the case with the Glide 
docking protocol and is considered to be due to the larger phenylalanine P2 residue being 
unable to fit into the S2 subsite of the enzyme. It was considered that the InducedFit protocol 
may permit the active site to flex enough to overcome the bulkier P2 side chain and allow the 
ligand to dock with the correct criteria, but this was not the case. 
 
Using the InducedFit protocol allowed compound B3 to fit into the active site in an 
extended β-strand conformation with all required criteria bar one „ugly‟ internal contact 
(Table 4.5 and middle Figure 4.13). This was not the case when it was docked using the 
Glide protocol. 
 
B4 was unable to dock appropriately using the Glide protocol or the InducedFit protocol  
(Table 4.5 and right Figure 4.13). 
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Figure 4.14; Best docked pose of compound C1 (left) and compound C2 (right). All docked with the Induced 
Fit protocol into the InducedFit µ-calpain model 
 
Compound C1 docked with the Glide protocol in the required manner (Figure 4.7) but 
unexpectedly the InducedFit protocol did not allow the ligand to dock appropriately (Table 
4.5 and left Figure 4.14). Conversely, compound C2 did not dock appropriately with the 
Glide protocol but did dock with the essential criteria when the InducedFit protocol was 
employed (Table 4.5 and right Figure 4.14), however, the phenylalanine side chain of the 
ligand is twisted in order to fit into the S2 subsite of the enzyme causing it to have a high 
number (six) „ugly‟ internal contacts. 
 
In summary, the Glide docking protocol takes up a lot of computer time and the 
InducedFit docking protocol takes up considerably more. To run the entire 288 compounds 
through these two docking protocols exceeded our computer time. For this reason we needed 
to test our methodology first.  
 
It was for this reason that we tested our docking methodology on 10 macrocyclic 
compounds by first docking with Glide into the active site of the enzyme model. The data 
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collected from this initial docking study of the 10 selected compounds found that compounds 
A1, A4, and C1 docked into the enzyme model in poses analogous to that found in 
compounds seen in co-crystallised X-ray structures found in the PDB
20-22
, and in a way that 
adhered to our criteria for good inhibitors, namely having the three essential H-bonds, close 
warhead to nucleophile distance, and low Glide and Emodel scores. The other seven 
compounds could not dock in this way.  
 
This initial Glide docking study revealed (by way of a visual inspection) that six of the 
seven compounds that did not dock appropriately were in poses that were not in the required 
β-strand conformation. An inspection of the lowest energy conformers used for docking 
revealed that these six compounds had their lowest energy conformer in a conformation that 
was not a β-strand. It was thought that using a non-β-strand conformer as a starting structure 
for Glide docking may result in these compounds not docking appropriately due to Glide not 
allowing for a rigorous search of conformational space for the potential inhibitor. The lowest 
energy conformer in a β-strand for each of these six compounds was then identified and Glide 
docking performed using these conformers. This allowed three more compounds (B1, B2, 
and B3) to dock with the essential criteria except for compound B2 missing an essential H-
bond resulting from the large P2 side chain being unable to fit into the deep S2 subsite and 
resulting in the ligand being positioned higher and out of the active site. 
 
Overall, six out of the ten compounds (A1, A4, B1, B2, B3 and C1) could dock in the 
required manner when the lowest energy conformer in a β-strand for each compound was 
used as the starting conformer in the Glide docking study. However, some of these 
compounds were found to have a small number of „ugly‟ internal contacts which were 
thought to be a consequence of Glide treating the enzyme model as a rigid structure (this is 
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not the case in nature) which forces the large macrocycle compounds to dock in a slightly 
„forced‟ manner. It was thought that if the enzyme model was allowed to „relax‟ a little that 
this would also allow the docked compounds to „relax‟ and this would see the elimination of 
some or all of the „ugly‟ internal contacts. It was for this reason that Schrodingers InducedFit 
protocol was employed. It was also hoped that the InducedFit protocol would allow 
compounds such as A2 with a large phenylalanine side chain and compounds with larger 
macrocycle rings to position into the active site pocket appropriately. 
 
The ten compounds used in the initial Glide docking study were then docked using the 
InducedFit docking protocol into the calpain enzyme model. Of the compounds A1, A2, A3, 
and A4 only A2 did not display the essential criteria. As discussed earlier it was considered 
that the InducedFit „movement‟ of the enzyme model would allow the enzyme to be more 
flexible and would help overcome compound A2‟s larger P2 side chain and allow the 
compound to fit into enzyme model but this proved not to be the case. 
 
Of the compounds B1, B2, B3, and B4 only B2 and B4 did not dock appropriately. B2 is 
similar to A2 as it has a phenylalanine P2 side chain and it is likely it suffers from that same 
problem as A2. B4 is analogous to A4 but has a larger macrocycle ring by one bond and it is 
probable that this larger ring size causes the compound not to dock in the required manner 
due to its size. 
 
While C1 docked appropriately in the initial Glide docking it did not dock in the same 
way when the InducedFit protocol was used. Although C2 was able to dock with the essential 
criteria when InducedFit was used, a high number of „ugly‟ internal contacts were evident 
4   Molecular modeling of cyclic inhibitors 
 
 109 
due to the phenylalanine side chain being twisted in order to fit into the deep S2 subsite of the 
enzyme. 
The results of the InducedFit docking studies on compounds A1-A4, B1-B4, C1 and C2 
(Table 4.5) indicated that compounds A1, A3, A4, B1, and B3 are potentially good inhibitors 
of calpain. Two of these compounds (A1 and B1) were prepared based on the modelling 
results and availability of the required chemicals for synthesis. They were tested in house and 
were shown to inhibit calpain in vitro with IC50‟s of 3710 and 280 nM, respectively. A valine 
side chain at the P2 position appears to be a better candidate than a phenylalanine at the same 
position as the latter seems to hinder docking of macrocycles A2, B2, and C2. 
 
As discussed above, the Glide and InducedFit docking protocols take considerable 
computer time on the basis of the above study of 10 macrocyclic compounds. It was therefore 
decided that the 288 compound library would first be examined by analysis of the 
conformational search outputs to establish the compounds with a marked propensity for β-
strand conformations. From this study the best were selected for subsequent docking with the 
InducedFit Protocol.   
 
4.3.3  Determination of Boltzmann weighted percentage of β-strand 
conformers within the macrocycle library of low energy ensembles 
 
Earlier observations revealed that not all of the lowest energy conformers for each of the 
288 compounds were in a β-strand. The occurrence of a γ-turn was unexpected and 
problematic because on further examination it was noticed that many of the ensembles 
contained mixtures of γ-turns and β-strand. Docking of γ-turn conformers causes a problem 
because within the small binding pocket the rotational freedom is more restricted. The Glide 
4   Molecular modeling of cyclic inhibitors 
 
 110 
docking program does not allow the peptide backbone to 'flip' from a γ-turn to a β-strand (and 
vice versa) within the binding pocket. Therefore, docking a macrocycle in a γ-turn 
conformation gives docking poses with the macrocycle only in a γ-turn conformation. 
 
It was necessary to conduct an analysis of the 288 macrocycles in the virtual library to 
identify appropriate conformers to use to initiate docking. By determining the Boltzmann 
weighted percentage of β-strand for each macrocycles low energy ensemble we could 
eliminate compounds that do not prefer a β-strand conformation while identifying compounds 
that do favour a β-strand. This was thought to be an important step because a compound that 
could not form a β-strand would in theory not be able to bind the active site of calpain and 
consequently effect inhibition of the enzyme. Compounds that could form a β-strand but do 
not prefer a β-strand conformation would in theory be less effective inhibitors than 
compounds that did prefer such a bioactive conformation. 
 
Firstly, a visual inspection of the ensembles of conformers of each macrocycle was 
conducted along with an analysis of some in silico interatomic measurements which were 
used to define parameters (albeit arbitrary) to allow a turn, a strand, and a 'twist' conformer to 
be identified.  
 
For example, the interatomic distance between the P2 backbone oxygen and the P2 
backbone NH hydrogen in the left picture of Figure 4.15 measures 2.485 Å and is indicative 
of a β-strand and the analogous interatomic distance of 3.777 Å in the right picture is 
indicative of a γ-turn. The parameter I used is as follows; If the interatomic distance between 
the P2 backbone oxygen and the P2 backbone NH hydrogen is < 3.1 Å the macrocycle was 
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identified as a β-strand, when > 3.6 Å a γ-turn, and between 3.1 and 3.6 Å a 'twist' conformer. 
These interatomic distances are easily tabulated for all ensemble conformers. 
A.      B 
Figure 4.15. A Macrocycle with typical β-strand conformation showing an interatomic distance between the 
carbonyl O atom and the amino H atom of the central leucine residue of 2.485 Å. B. Macrocycle with typical γ-
turn conformation showing an interatomic distance measurement of 3.777 Å. R can be any capping group such 
as BOC. X can be any two side-chains able to be joined, for example, by ring closing metathesis.  
 
 
I attempted to calculate the Boltzmann weighted percentage of strand, turn, and 'twist' 
conformers for each low energy ensemble of macrocycle using this method. 
 
In order to calculate this data, a spreadsheet was established that would calculate the 
Boltzmann weighted percentages when the potential energy and interatomic parameters for 
each conformer was entered. An example of this spreadsheet is shown below in Table 4.6. 
 
Table 4.6. A section of the spreadsheet used to calculate the Boltzmann weighted percentages of conformers 
exhibiting turn, strand, and 'twist'. 
 
R
X
R
X
A B C D E F G H I J K L M N
Energy E/kT e-E/kT Ne-E/kT Boltzmann % E*%  Distance 18-24Bolt .Ave.E Strand Turn Twist % Strand % Turn %
-316.54 126.9 # # # # # # 2.23 24.76 -7837.15 2.28 -314.9 24.76 0 0 100 0
-316.06 126.71 # # # # # # 1.84 20.4 -6448.01 2.2 20.4 0
-314.42 126.05 # # # # # # 0.95 10.6 -3332.98 2.19 10.6 0
-313.9 125.85 # # # # # # 0.77 8.61 -2702.56 2.13 8.61 0
-313.9 125.84 # # # # # # 0.77 8.59 -2697.93 2.18 8.59 0
-313.87 125.83 # # # # # # 0.76 8.49 -2665.43 2.55 8.49 0
-313.69 125.76 # # # # # # 0.71 7.92 -2483.7 2.18 7.92 0
-312.73 125.38 # # # # # # 0.48 5.38 -1684.01 2.17 5.38 0
-312.66 125.35 # # # # # # 0.47 5.24 -1638.39 2.12 5.24 0
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Column title meanings: 
A  Potential energy of each conformer calculated by the OPLS2005 force field. 
B, C, D, E Each column calculates the Boltzmann weighting of each conformer from the 
expression 
   
exp[-(E  /kBT]
exp[-(E  /kBT]
NA
-
=P
 
B E/kT where E = negative potential energy (the negative of column A), k = Boltzmann 
constant (8.32441 J · K-1 · mol-1), T = temperature (300K). 
   Formula =(-A2*1000)/(8.31451*300) 
C  e-E/kT, e = natural log. Formula =IF(B2=0,0,EXP(B2)) 
D Ne-E/kT, N = number of conformers (entries in column A).  
Formula =COUNT($A$2:$A$300)*(C2) 
E Boltzmann. Final calculation performed to give the Boltzmann weighting of each 
conformer (entries in column A).  
Formula =(D2)/SUM($C$2:$C$300) 
F %. Calculates the Boltzmann weighted % of each conformer.  
Formula =(E2)/SUM($E$2:$E$300)*10 
G E*%. Potential energy (column A) x Boltzmann weighted % (column F).  
Formula =(A2*F2) 
H  Interatomic distances between the O atom and H atom indicated in Figure 2. 
I Bolt.Ave.E. Calculates the Boltzmann average potential energy within 12 kJ of the 
lowest energy conformer.  
Formula =SUM(G2:G300)/100 
J Calculates the Boltzmann weighting of conformers exhibiting a β-strand. 
Formula  =IF(H3>3.1;0;F3). 
K Calculates the Boltzmann weighting of conformers exhibiting a γ-turn.  
Formula  =IF(H3<3.6;0;F3). 
L Calculates the Boltzmann weighted percentage of conformers exhibiting a 'twist' 
Formula =100-(SUM($J$2:$J$1046))-(SUM($K$2:$K$1046)). 
M Calculates the Boltzmann weighted percentage of conformers exhibiting a β-strand. 
Formula =SUM($J$2:$J$1046). 
N Calculates the Boltzmann weighted percentage of conformers exhibiting a γ-turn. 
Formula =SUM($K$2:$K$1046) 
 
 
 
 
The method worked well but was time consuming as the potential energies and the 
interatomic distances had to be cut and pasted into a spreadsheet for each macrocycle. A 
script was subsequently written with the help of Dr. Quentin MacDonald to calculate the 
Boltzmann weighted percentage of β-strand for each macrocycle. The script was written to 
identify β-strands based on the ψ (Psi) and φ (Phi) angles of the P2 amino acid of each 
compound. Ramachandran plots of ψ,φ angles in β-strand or β-sheet regions of protein X-ray 
crystal structures from the PDB show that typical ψ angles to be between 90º and 160º and 
that of φ angles to be between -90º and -160º.23 These parameters were used in the program to 
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determine the Boltzmann weighted percentage of β-strand for each macrocycle. The program 
script was run using the output files from the conformational searches performed on the 
macrocycles and the resulting data tabulated (Table 4.7). The table shows good candidates 
(green cells), average candidates (uncoloured cells), and poor candidates (red cells) 
depending on the Boltzmann weighted percentage of each macrocycle in a β-strand. It also 
has the ring size of each macrocycle at the bottom of each cell. 
 
Table 4.7. Each cell contains data relating to the equivalent 4-fluorobenzyl sulphonamide protected aldehydes 
A1, A2, A3...P16, P17, P18. The top of each cell shows the Boltzmann weighted percentage of each macrocycle 
in a β-strand, green cells shows macrocycles with >70% β-strand, uncoloured cells show between 30% and 70% 
β-strand, and red cells show <30% β-strand. The bottom of each cell shows the macrocycle ring size by number 
of bonds. 
a
 Compounds A8 and B7 are equivalent structures. 
b
 Compounds A9, B8, and C7 are equivalent structures. 
c
 Compounds B9 and C8 are equivalent structures. 
 
          Acid           
Ester 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
A 100 100 16 50 0 2 0 0 0 1 29 67 61 67 0 0 43 98 
  16 16 14 14 13 13 9 10
a
 11
b
 12 13 14 15 16 12 12 14 16 
B 57 27 8 6 28 2 0 0 2 24 21 29 88 63 1 7 74 39 
  17 17 15 15 14 14 10
a
 11
b
 12
c
 13 14 15 16 17 13 13 15 17 
C 53 16 78 0 24 2 0 2 12 33 0 72 80 75 0 0 81 37 
  18 18 16 16 15 15 11
b
 12
c
 13 14 15 16 17 18 14 14 16 18 
D 28 15 0 41 3 1 68 29 28 20 21 7 7 5 34 17 1 2 
  21 21 19 19 18 18 14 15 16 17 18 19 20 21 17 17 19 21 
E 47 3 0 0 1 11 0 60 26 0 0 1 15 0 24 0 0 18 
  21 21 19 19 18 18 14 15 16 17 18 19 20 21 17 17 19 21 
F 63 23 0 0 15 0 27 37 43 10 27 0 48 18 29 5 36 13 
  20 20 18 18 17 17 13 14 15 16 17 18 19 20 16 16 18 20 
G 35 5 2 0 1 6 1 11 49 0 0 3 6 58 20 5 8 2 
  20 20 18 18 17 17 13 14 15 16 17 18 19 20 16 16 18 20 
H 95 47 7 0 68 32 0 16 65 0 0 38 30 4 83 18 25 1 
  19 19 17 17 16 16 12 13 14 15 16 17 18 19 15 15 17 19 
I 32 75 41 0 12 4 34 30 98 0 80 63 26 8 26 0 24 13 
  20 20 18 18 17 17 13 14 15 16 17 18 19 20 16 16 18 20 
J 0 17 11 31 29 1 2 13 42 0 6 0 19 2 0 0 40 0 
  21 21 19 19 18 18 14 15 16 17 18 19 20 21 17 17 19 21 
K 10 0 43 0 22 0 85 89 71 0 0 2 55 1 0 0 0 13 
  22 22 20 20 19 19 15 16 17 18 19 20 21 22 18 18 20 22 
L 52 5 0 0 0 3 1 2 9 0 0 0 53 0 0 0 0 0 
  23 23 21 21 20 20 16 17 18 19 20 21 22 23 19 19 21 23 
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M 4 0 0 0 6 0 0 0 1 0 0 25 68 0 3 0 38 0 
  19 19 17 17 16 16 12 13 14 15 16 17 18 19 15 15 17 19 
N 6 0 0 20 17 21 0 0 0 0 0 1 0 50 0 0 0 0 
  19 19 17 17 16 16 12 13 14 15 16 17 18 19 15 15 17 19 
O 8 6 88 21 28 0 0 0 60 0 0 0 11 0 4 0 0 0 
  21 21 19 19 18 18 14 15 16 17 18 19 20 21 17 17 19 21 
P 61 0 0 0 2 0 92 94 0 8 0 3 0 3 1 1 0 4 
  23 23 21 21 20 20 16 17 18 19 20 21 22 23 19 19 21 23 
 
 
 
Twenty compounds that were found to have a more than 70% Boltzmann weighted 
preference for a β-strand conformation (green cells) are shown in Table 4.7. Seven of these 
have a 90% Boltzmann weighted preference for a β-strand conformation. These seven were 
chosen to be docked into the enzyme model using the InducedFit protocol.  
 
For docking of these compounds the InducedFit Protocol was chosen as it was hoped that 
it might allow some of the larger compounds to fit into the active site which had been shown 
in the previous study. It had already been shown that compound A2 could not be docked into 
the rigid enzyme model using Glide alone and that this was likely due to the bulkier side 
chain compared to the similar compound A1 as discussed earlier. 
 
The 20 compounds showing a 70% preference for a β-strand all have a ring size of 
between 15 and 19 bonds which is consistent with Fairlies
6
 assessment that ca 17 membered 
macrocycles prefer a β-strand conformation. Many of the compounds with smaller and larger 
ring sizes do not form a β-strand at all. 
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4.3.4  InducedFit docking of seven compounds with a >90% preference for 
a β-strand conformation 
 
Compounds A1, A2, A18, H1, I9, P7, and P8 (Figure 4.16) all have a >90% preference 
for a β-strand conformation and were docked using the lowest energy conformer in a β-strand 
and Schrodinger‟s InducedFit Protocol (parameters used are shown in Protocol 5 in the 
Appendix). Compounds A1 and A2 were actually docked with InducedFit earlier as part of 
the docking study in Section 4.1.5 so will only be discussed briefly here. 
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Figure 4.16: Chemdraw pictures of compounds A1, A2, A18, H1, I9, P7, and P8 
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Table 4.8: Docking data for best pose (out of possible 20) and inhibitory concentrations (IC50) for compounds 
A1, A2, A18, H1, I9, P7, and P8 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
m-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
A1 -7.4 -84.0 3 4.2 217 17 0 3710 
A2 -7.4 -67.8 2 >5 274 26 0  
A18 -6.4 -69.6 2 3.5 378 31 13  
H1 -7.6 -87.3 3 3.5 295 15 0 2400 
I9 -6.9 -68.5 3 3.5 271 7 1  
P7 -5.1 -71.9 3 3.8 285 11 0  
P8 -8.0 -70.2 3 4.0 291 12 0  
 
Compounds A1 and A2 were docked using the InducedFit Protocol. Compound A1 
docks into the calpain InducedFit model with all the essential criteria in place. Compound A2 
could not bind in the required mode when the InducedFit protocol was employed. For further 
discussion on docking of compounds A1 and A2 see Section 4.1.5 above (Table 4.5 and 
Figure 4.11). 
 
Compounds H1 and P7 gave docked poses that had all the essential requirements for 
good calpain inhibition (Table 4.8 and Figure 4.17). In addition to having the three required 
H-bonds they both had two additional H-bonds. Both compounds had one of their extra H-
bonds formed between a sulfonyl oxygen from the capping group and the side chain of 
Asn253. The compounds also have an additional H-bond formed between the warhead 
aldehyde oxygen and the side chain of His272. These extra H-bonds would increase the 
binding affinity in a real biological system. 
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Figure 4.17; Best docked pose of compound H1 (left) and compound P7 (right). All docked with the Induced 
Fit protocol into the InducedFit µ-calpain model 
 
The additional data for compounds H1 and P7 is also encouraging as both have a close 
distance between the warhead and nucleophile (3.5 and 3.8, respectively), and good Glide 
and Emodel scores, and their best poses display no „ugly‟ internal contacts. 
 
Figure 4.18 shows the best docked poses of P8 (left), I9 (middle), and A18 (right). P8 
and I9 have the three essential H-bonds and all other necessary criteria for good calpain 
inhibition (Table 4.8). Compound P8 also has an additional H-bond formed between a 
sulfonyl oxygen from the capping group and the side chain of Asn253. 
 
Compound A18 seems to be suffering from the same problem as A2, B2, and C2 in the 
previous docking study because of its bulkier P2 side chain, in this case a cyclohexanyl group. 
This group only partially fits into the S2 subsite of the enzyme models active site but the β-
strand backbone of the ligand is sitting higher in the pocket and consequently one of the 
essential three H-bonds cannot form. 
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Figure 4.18; Best docked pose of compound P8 (left), compound I9 (middle), and compound A18 (right). All 
docked with the Induced Fit protocol into the InducedFit µ-calpain model 
 
In summary, the compounds A1, A2, A18, H1, I9, P7, and P8 from the 288 compound 
library were selected for InducedFit docking studies because their low energy conformational 
ensembles showed each of these compounds had a high propensity for having β-strand 
conformations. All had a greater than 90% Boltzmann weighted preference for a β-strand 
(Table 4.7). 
 
As previously discussed compound A1 had all the docking criteria indicating it to be an 
active inhibitor of calpain, while compound A2 did not dock in the required way because of it 
having a larger P2 side chain. Compound A18 suffered from a similar problem to A2 with 
having a bulky P2 side chain that prevented it from docking with all three essential H-bonds. 
Like compound A1, compounds H1, I9, P7, and P8 had good InducedFit docking results and 
showed promise as possible inhibitors of calpain. 
 
As a result of these docking studies, compounds A1, B1, and H1 were chosen as targets 
for synthesis by members of the cataract research team. These compounds were subsequently 
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tested in vitro and were shown to inhibit ovine m-calpain at 3710, 280, and 2400 nM, 
respectively. 
 
4.3.5  InducedFit docking: Analogues of macrocyclic compounds A1, B1, 
C1, and H1 
 
To further our study on the macrocycle compounds, the macrocycle core of compounds 
A1, B1, C1 and H1 were used as templates to add a different capping group, a different P2 
side chain, and a different warhead. The templates of compounds A1, B1, and H1 were 
chosen because they had been shown to be inhibitors of calpain with varying degrees of 
potency in the previous study. The template of C1 was chosen as it was an analogous 
molecule to A1 and B1 but had a larger macrocycle ring and docking data of this compound 
had previously been inconclusive as it had seemingly docked well with Glide but had failed 
to dock appropriately when InducedFit was used (Sections 4.1.4 and 4.1.5, respectively). For 
the following study a Cbz group was chosen as an alternative capping group for a series of 
compounds with the above mentioned templates. 
 
The previous sections showed that phenylalanine at the P2 position to be too large to fit 
into the deep hydrophobic pocket of the S2 subsite while a smaller valine at this position 
proved to be a better fit. As a compromise, leucine, which is larger than valine but smaller 
than phenylalanine and still a hydrophobic amino acid, was investigated at the P2 position.  
 
To overcome the problems previously discussed with respect to the aldehyde warhead 
being too reactive with other cellular proteins
10
 to be considered as a good drug candidate we 
decided to replace the aldehyde with an alcohol. An alcohol was thought to be a good 
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candidate because, although not a warhead as such, it would mimic the tetrahedral 
intermediate formed when the aldehyde reacts with the active site cysteine of the calpain 
enzyme, as is seen in PDB X-ray structures like 2G8E,
20
 and although these compounds 
would not form a reversible covalent bond with the active site cysteine the trade off with 
them not reacting with other proteins in a biological system was thought to be worth 
examining. These compounds can be seen in Figure 4.19 
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Figure 4.19: Structures of compounds 4.9-4.20 
 
Table 4.9: Docking data for best pose
a
 (out of possible 20) and inhibitory concentrations (IC50) for compounds 
4.9-4.20 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
m-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
4.9 -8.3 -71.3 3 3.4 277 17 1  
4.10 -8.4 -86.6 3 3.7 307 22 2 850 
4.11 -9.7 -83.7 3 NA 311 26 5 31000 
4.12 -8.0 -78.1 3 3.9 280 18 1 85 
4.13 -4.5 -67.3 3 4.0 309 20 1 30 
4.14 -9.0 -77.5 3 NA 340 24 2 700 
4.15 -7.8 -84.9 3 4.1 303 18 0  
4.16 -10.0 -69.1 3 4.0 325 14 3 180 
4.17 -10.1 -82.8 3 NA 313 21 1 1100 
4.18 -9.2 -87.5 3 4.2 285 14 1 295 
4.19 -9.7 -66.4 3 4.8 314 21 2 1010 
4.20 -9.4 -79.3 0 NA 347 26 8 28000 
 
a
  best pose chosen by criteria in order of importance; 1 - presence of three essential hydrogen bonds, 2 - 
warhead within 5Å of nucleophilic Cys115, 3 - low Glide score/emodel score, 4 - lowest number of internal 
ugly contacts. 
 
b
  GlideScore
18
 is a scoring function based on ChemScore
19
 which is designed to estimate free energy of binding 
for protein–ligand complex. The function uses simple contact terms to estimate lipophilic and metal–ligand 
binding contributions, a simple explicit form for hydrogen bonds and a term which penalises flexibility. 
 
c
  Emodel
18
 is a model energy score that combines energy grid score, binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy. 
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Compounds 4.9, 4.10, and 4.11 docked into the enzyme model with all the essential 
criteria (Table 4.9 and Figure 4.20). These compounds had β-strand percentages of 99%, 
100%, and 99%, respectively, showing that they strongly preferred this conformation (Table 
4.10). In addition to the three essential H-bonds, compound 4.10 had an extra H-bond 
between the amide oxygen at the capping group end to the side chain of Asn253. The IC50 for 
4.10 was recorded at a moderately good 850 nM.  
 
Compounds 4.9 and 4.10 had only one and two „ugly‟ internal contacts, respectively. 
However, compound 4.11 displayed five „ugly‟ internal contacts which is a possible 
indication that it was not a good fit into the enzyme and may be why the IC50 for this 
compound turned out to be particularly high (31000 nM). However, a lower IC50 is expected 
for the compounds with an alcohol „warhead‟ as they do not form a covalent bond. 
 
Table 4.10: The Boltzmann weight percentage of conformers within a 12kJ window displaying a β-strand for 
compounds 1-12 and the macrocycle ring size for each compound. 
 
Compounds 
 4.9 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 
% β-strand 99 100 99 65 8 75 89 85 53 35 39 0 
Macrocycle  
ring size 
16 16 16 17 17 17 18 18 18 19 19 19 
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Figure 4.20: Best docked poses of compounds 4.9, 4.10, and 4.11 using the InducedFit protocol docked into the 
calpain model. 
 
Compounds 4.12, 4.13, and 4.14 also demonstrated a preference to bind in the 
appropriate way (Table 4.9 and Figure 4.21). Extra H-bonds were seen in the best docked 
pose of compound 4.12, one between the aldehyde warhead oxygen and the side chain of 
Cys115, and the other from the backbone oxygen of the P3 residue to the side chain of 
Asn253. When tested in vitro compound 4.12 had an excellent IC50 of 85 nM, one of the most 
potent in the series. It also has a ring size of 17 which fits with Fairlie‟s6 assessment of 
having a ca 17 membered ring to favour a β-strand. 
 
Figure 4.21: Best docked poses of compounds 4.12, 4.13, and 4.14 using the InducedFit protocol docked into 
the calpain model. 
 
Compound 4.13 was shown to be the most potent compound in vitro with an excellent 
IC50 of 30 nM against ovine m-calpain (Table 4.9). The larger leucine side chain (compared 
to valine) at the P2 position fits into the deep hydrophobic pocket of the S2 subsite without 
problem (Figure 4.21). Changing from a valine (compound 4.12) to a leucine (compound 
4.13) has had a positive effect on the IC50. It has the optimal macrocyclic ring size of 17. 
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Compound 4.14 has an IC50 of 700 nM which is particularily good considering it has an 
alcohol in place of the usual aldehyde warhead. The alcohol forms a H-bond with the side 
chain of Gly271 (Figure 4.21 left) and is unexpectedly pointing away from the oxyanion hole 
(usually formed by two stabilising H-bonds, one between the oxyanion of a tetrahedral 
intermediate and the backbone NH of Cys115 and the other between the oxyanion and the 
side chain of Gln109).
20
 
 
Compounds 4.15, 4.16, and 4.17 all bind to the active site pocket with the required 
criteria. All have two extra H-bonds in addition to the three essential H-bonds required for 
good binding (Figure 4.22 left). Compound 4.16 has three „ugly‟ internal contacts but when 
synthesised and tested against m-calpain it has a good IC50 of 180 nM suggesting that the 
three „ugly‟ contacts could be accommodated by the enzyme.  
 
 
Figure 4.22: Best docked poses of compounds 4.15, 4.16, and 4.17 using the InducedFit protocol docked into 
the calpain model. 
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Figure 4.23: Left; Picture of X-ray crystal of compound SNJ-1715 bound to mini µ-calpain (PDB code 2G8E)
20
 
showing the three essential H-bonds to Gly208 and Gly271 and the two stabilising H-bonds from the oxyanion 
to the side chain of Gln109 and the backbone NH of Cys115. Right; Chemdraw depiction of SNJ-1715 bound to 
the active site of µ-calpain (PDB code 2G8E).
20
 Enzyme (red), inhibitor (black), and H-bonds (blue). 
 
 
Compound 4.17 has an alcohol at the „warhead‟ end and its best docked pose shows that 
it is positioned closely to the oxyanion hole but forming a H-bond to the side chain of Gly113 
instead of Cys115 and Gln109. It cannot form the usual H-bonds to Cys115 and Gln109 as it 
is positioned higher in the pocket than is usually seen when an aldehyde or similar type 
warhead covalently binds to the active site cysteine and the oxyanion of the tetrahedral 
intermediate forms these two H-bonds as seen in the PDB X-ray structure 2G8E (Figure 4.23 
right).
20
 
 
Compound 4.18 fitted into the active site with all the required criteria (Table 4.9 and 
Figure 4.24). It had two extra H-bonds, one from the carbonyl oxygen at the capping group 
end to Asn253 and the other from the aldehyde warhead to the side chain of Cys115. It was 
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synthesised and tested and gave an IC50 of 195 nM. 4.18 has a valine at the P2 position while 
the analogous compound 4.19 has a leucine at this position.  
Figure 4.24: Best docked poses of compounds 4.18, 4.19, and 4.20 using the InducedFit protocol docked into 
the calpain model. 
 
Compound 4.19 also docks with the appropriate criteria and has two additional H-bonds. 
However, the exchange of the valine for a leucine has negatively affected the IC50 which is 
1010 nM. The effect of the different P2 side chains on the IC50‟s of these two compounds is 
the opposite to what is seen with compounds 4.12 and 4.13 where the effect of changing from 
a valine (compound 4.12) to a leucine (compound 4.13) had a positive effect on the IC50. 
 
The percentage of conformers within a 12 kJ/mol window found to be in a β-strand for 
compound 4.20 was calculated at 0% (Table 4.10). This means that compound 4.20 did not 
produce one β-strand conformation in the 12kJ/mol conformational search and strongly 
favours a turn type conformation. Predictably, when the lowest energy conformer of 4.20 was 
docked into the enzyme model the docked poses returned had the compound in a turn type 
conformation which cannot form the three essential H-bonds. The compound had a bad IC50 
of 28000nM. Because 4.20 does not appear to form a β-strand and favours a turn 
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conformation it is likely that in a real system it cannot form a β-strand and bind the enzyme 
favourably. 
 
In summary, compounds 4.9, 4.12, 4.15 and 4.18 form a series of Cbz protected aldehyde 
macrocycles with a valine at the P2 position. Previous studies had shown that when a 
macrocycle with a valine at this position was docked into the enzyme model the valine side 
chain could fit into the deep hydrophobic S2 subsite favourably and this was the case here 
with all other criteria met as well. Compounds 4.9 and 4.15 were not synthesised, however, 
compounds 4.12 and 4.18 were both synthesised and tested and proved to be effective calpain 
inhibitors. 
 
Compounds 4.10, 4.13, 4.16 and 4.19 are a series of compounds based on the compounds 
4.9, 4.12, 4.15 and 4.18, respectively, except the valine at the P2 has been replaced by a 
leucine. Previous studies showed that a phenylalanine at the P2 position to be too large for 
optimal docking, however, the docking of compounds 4.10, 4.13, 4.16 and 4.19 provided 
strong evidence that a leucine at the P2 position could comfortably dock into the S2 subsite. In 
fact compound 4.13 was synthesised and tested to be our most potent compound synthesized 
in house with an IC50 of 30 nM and was shown to retard calcium-induced cataract in cultured 
ovine lenses. Compound 4.16 had a healthy IC50 of 180 nM. 
 
Compounds 4.11, 4.14, 4.17 and 4.20 are a series of compounds that are analogous to the 
compounds 4.10, 4.13, 4.16 and 4.19, respectively, with the aldehyde warhead changed for an 
alcohol. Because aldehydes are notoriously known to react with other molecules under 
cellular conditions
10, 25
 it was hoped that changing the warhead to an alcohol would still allow 
the compounds to inhibit calpain by mimicking the tetrahedral intermediate which is 
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stabilised by H-bonds in the oxyanion hole. If their respective IC50‟s were not as good as their 
aldehyde counterparts, it was hoped that the trade off in potency would overcome the 
aldehydes innate reactivity to other proteins under cellular conditions.  
 
The modelling results showed that compounds 4.14 and 4.17 were potentially good 
calpain inhibitors with all the essential criteria for good inhibition met. The compounds were 
synthesised in house and proved to be moderately good inhibitors. At about 1-2 orders of 
magnitude less potent than their aldehyde counterparts, 4.13 and 4.16,  they are interesting 
compounds because unlike the aldehydes they cannot form a covalent bond to the enzyme yet 
are able to inhibit the enzyme to a moderate degree. They have yet to be tested in vivo to see 
if the trade off in potency is overcome by their proposed lesser tendency to react with other 
cellular proteins. 
 
Compound 4.11 did meet the main docking criteria, and, the best poses had a high 
number of „ugly‟ internal contacts which suggested that the compound was being slightly 
„forced‟ into the active site of the enzyme model in order to fit and would not be a good 
inhibitor. It turns out that the compound has a very poor IC50 of 31000 nM 
 
The conformational search results of compound 4.20 and the subsequent β-strand 
analysis showed that it did not form a β-strand. The lowest energy conformer of the 
compound, which happened to be a turn type conformation, was docked. The predictable 
outcome of the docking was that it could not dock with the required criteria and the 
compound docked in the original turn type conformation. Because it could not form a β-
strand within the enzyme pocket it was predicted that it would be a poor inhibitor of calpain. 
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In fact this compound was made and tested to have an IC50 of 28000 nM, a very poor 
inhibitor of calpain. 
 
4.3.6 In Vivo study of compound 4.13 (CAT811) 
 
We next chose to investigate the potential of our most potent potential inhibitor, 
compound 4.13, to retard the development of calcium-induced cortical cataracts, which have 
been linked to an overactivity of ovine m-calpain.
24
 Lenses from 9-12-month-old lambs were 
incubated for 48 h in EMEM (Eagle Minimum Essential Medium) culture medium (10 mL) at 
37 °C in 5 % CO2. Compound 4.13 (1 µM) was added to one lens of each of six pairs of 
sheep lenses in the culture medium. After incubation for 3 h, CaCl2 was added to a final 
concentration of 5 mM. Intact ovine lenses (n=6) were also incubated in EMEM culture 
medium as a control. After 6 h, all lenses were photographed over a grid, and the opacity was 
graded by using the software Image-Pro 4.1. Lenses treated with only calcium showed 
substantial opacity as associated with cataract formation. The presence of compound 4.13 
prevented this calcium-induced opacification, and these lenses remained essentially 
transparent after incubation for 6 h (Figure 4.25). Thus, compound 4.13 in the culture 
medium was able to significantly reduce lens opacity.  
 
Figure 4.25: Effect of compound 4.13 on calcium-induced cataract formation in cultured ovine lenses. The 
values given are the mean opacification grading score (SEM: standard error of the mean) in each case and 
represent the mean opacity of six lenses. Fully opaque lenses have scores of 80-100, whereas transparent lenses 
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have scores of less than 20. a) control: (16.0 ± 2.1); b) Ca
2+
 only: (58.8 ± 6.7); c) Ca
2+
 with compound 4.13: 
(16.7 ± 1.5). 
 
In summary, compound 4.13 (also known as CAT811), the most potent compound in 
vitro with an IC50 of 30 nM, was tested in an in vivo ovine lens model to see if it could retard 
the formation of cortical cataracts in ovine lenses. The results of this test showed that 
compound 4.13 could retard cataract formation in ovine lenses significantly. 
 
4.3.7  Additional modification of macrocyclic cores: docking studies of 
macrocyclic diols 
 
In the previous section (Section 4.1.8) the core macrocycles from Section 4.1.7 were 
modified by the substitution of the capping group with Cbz which proved to be a capping 
group worth investigating further.   The studies in Section 4.1.8 also indicated that leucine at 
the P2 position for the Cbz compounds was worthy of further study.  
In addition, compound P8 had been shown (Section 4.1.7) to dock into the calpain model 
using InducedFit with good criteria, therefore, the core of this macrocycle was modified by 
substiution with Cbz and leucine at the P2 position (compound 4.21 Figure 4.26).  
 
The macrocyclic alkene of compound 4.21 was oxidised to diol which gave compounds 
4.22 and 4.23 (Figure 4.26). It was hoped that docking of these diols would show that the 
alcohol groups could protrude out of the active site pocket, when the macrocycle is bound in 
the appropriate way, and into the surrounding hydrophilic environment and that this would be 
favourable for binding.  
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Figure 4.26. Chemical structures of the compounds 4.21, 4.22, and 4.23. 
 
 
Table 4.10: Docking data for best pose
a
 (out of possible 20) and inhibitory concentrations (IC50) for compounds 
4.21-4.23 
 
 
 Glide emodel Essential Warhead  Internal contacts IC50 (nM) 
m-calpain Compound Score
b 
Score 
c 
H bonds Distance 
Å 
Good Bad Ugly 
4.21 -9.2 -73.6 3 3.9 309 17 0  
4.22 -8.1 -74.4 3 4.3 325 19 1  
4.23 -10.3 -68.6 3 3.9 334 22 0  
 
 
a
  Best pose chosen by criteria in order of importance; 1 - presence of three essential hydrogen bonds, 2 - 
warhead within 5Å of nucleophilic Cys115, 3 - low Glide score/emodel score, 4 - lowest number of internal 
ugly contacts. 
 
b
  GlideScore
18
 is a scoring function based on ChemScore
19
 which is designed to estimate free energy of binding 
for protein–ligand complex. The function uses simple contact terms to estimate lipophilic and metal–ligand 
binding contributions, a simple explicit form for hydrogen bonds and a term which penalises flexibility. 
 
c
  Emodel
18
 is a model energy score that combines energy grid score, binding affinity predicted by GlideScore, 
and (for flexible docking) the internal strain energy. 
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Table 4.11: The Boltzmann weight percentage of conformers within a 12kJ window displaying a β-strand for 
compounds 4.21-4.23 and the macrocycle ring size for each compound. 
 
Compounds 1 2 3 
% β-strand 74 46 10 
Macrocycle  
ring size 
17 17 17 
 
The three compounds were docked using Protocol 5 in the Appendix and all display the 
three essential hydrogen bonds from the β-strand backbone to Gly208 and Gly271 of the 
enzyme (Table 4.10 and Figures 4.27, 4.28, and 4.29). The distances between the 
electrophilic carbon of the ligand and the nucleophilic sulphur of the enzymes active site 
Cys115 are within 5Å. This indicates that they are close enough for nucleophilic attack by the 
cysteine sulphur to occur. 
 
Compound 4.21 has an additional hydrogen bond from the carbonyl oxygen of the Cbz 
group to Lys347 NH3
+
 group. Compound 4.22 has an additional two hydrogen bonds, one 
from the aldehyde oxygen to the Cys115 SH, the other from the ether oxygen of Cbz to the 
NH2 of Asn253. The Glide scores are all low ca -9 which indicates strong binding energies 
for the enzyme ligand complexes. 
 
All three compounds are positioned within the active site with the backbone being in the 
favoured β-strand conformation.  The rest of the macrocyclic rings of 4.21, 4.22 and 4.23 
protrude towards the outside of the cavity along with the diol groups of compound 4.22 and 
4.23. The leucine side chain of all three compounds positioned deep in the hydrophobic 
region of the active site. 
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Figure 4.27. Left - lowest energy conformer of compound 4.21.  
Right – best pose of lowest energy conformer of compound 4.21 docked into the enzyme model. Dotted yellow 
lines show hydrogen bonds between ligand and enzyme. 
 
 
 
 
Figure 4.28. Left - lowest energy conformer of compound 4.22 (S,S-diol).  
Right – best pose of lowest energy conformer of compound 4.22 docked into the enzyme model. Dotted yellow 
lines show hydrogen bonds between ligand and enzyme. 
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Figure 4.29. Left - lowest energy conformer of compound 4.23 (R,R-diol).  
Right – best pose of lowest energy conformer of compound 4.23 docked into the enzyme model. Dotted yellow 
lines show hydrogen bonds between ligand and enzyme. 
 
Areas of hydrophobicity and hydrophilicity on the surface of the enzyme crystal structure 
1KXR around of the active site are shown in Figure 4.30. The top two diagrams show the 
hydrophobic and hydrophilic areas of 1KXR which has no bound ligand.  
 
When the three compounds are docked (bottom three diagrams of Figure 4.30) the 
hydrophobic leucine side chain fits deep into the hydrophobic pocket of the enzyme. The 
long hydrophobic area at the top of both top pictures is occupied by the hydrophobic Cbz ring 
in the bottom three diagrams. 
 
The other large hydrophobic area seen at the right of the top two diagrams (Figure 4.30) 
is an area that changes when each of the three ligands is bound and in a different manner for 
each ligand. This hydrophobic region sits above the side chain diol regions of compounds 
4.22 and 4.23. The diol regions of these two compounds occupy a proportion of this 
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hydrophobic surface which is necessarily unfavourable. Compound 4.21, in the absence of 
such a diol hydrophobic surface interaction, is much more favourably bound and may 
therefore be a better inhibitor than compounds 4.22 and 4.23.  
 
 
 
Figure 4.30. Sitemap and surface pictures. Top left – the active site of 1KXR showing area of hydrophobic 
surface in copper. Top right – the active site of 1KXR showing surface areas that are hydrophobic in a copper 
colour and the areas that are hydrophilic in a white. Bottom left – best pose of compound 4.21 docked into 
1KXR showing hydrophobic and hydrophilic surface areas. Bottom middle – best pose of compound 4.22 
docked into 1KXR showing hydrophobic and hydrophilic surface areas. Bottom right – best pose of compound 
4.23 docked into 1KXR showing hydrophobic and hydrophilic surface areas. 
 
The hydrophilic area around the opening to the active site pocket in the top right diagram 
of Figure 4.28 is due to the hydrophilic side chains of Cys 115, Ser 206, Thr 210, Ser 251, 
Asn 253, Lys 347, and Glu 349. The backbone NH and CO groups of Gly 207, Gly 208, and 
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Gly 271, which form the three essential hydrogen bonds between the enzyme and the ligands, 
also contribute to this hydrophilic area. The formation of these hydrogen bonds is therefore 
favourable for binding of the three ligands.  
 
In conclusion, all three compounds show the potential to be effective inhibitors of 
calpain due to their good Glide scores, formation of the three essential hydrogen bonds, and 
the close proximity of the warhead (aldehyde) to the nucleophilic sulphur of the enzyme. 
 
At the time of writing this thesis we have not received any test results from Joanne 
Duncan the PhD student who prepared these compounds. 
 
4.4 Conclusion 
 
Cyclization of an inhibitor can reduce their entropic flexibility and constrain the 
molecule to have propensity for a bioactive conformation. In this case it was preferable to 
lock the potential inhibitors into a β-strand, a known bioactive conformation for substrates of 
proteases. 
 
Our first attempt to design cyclic analogues of SJA-6017 was completed before 
molecular modelling was used as a tool in the design of calpain inhibitors and before any 
suitable crystal structures of the enzymes were available to our group. Postdoctoral fellow Dr 
S Miyamoto carried out the first synthetic work on cyclic inhibitors in our research group 
which was key to establishing ring closing metathesis as a suitable but expensive synthetic 
strategy, The 8-membered cyclic analogues of SJA-6017 were subsequently shown by 
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molecular modelling to be non- β-strand mimics and therefore it is not surprising that they 
did not inhibit m-calpain in vitro. 
 
It became increasingly apparent through molecular modelling and literature studies that 
the β-strand was critical for protease recognition, and therefore inhibition, and that it would 
be advantageous to design cyclic inhibitors that are locked into this bioactive conformation. 
This drove our research effort to the design of macrocyclic inhibitors that could mimic a β-
strand conformation. 
 
A 288 compound library of possible macrocyclic tri-peptide compounds was proposed 
with considerable input from Dr Steve Aitken. A selected sample of ten of these compounds 
was docked using Glide into the enzyme model and this provided evidence that some of these 
ten compounds could dock into the active site in a fashion that indicated their potential as 
good inhibitors. It was noticed that some of the compounds could not dock because of turn-
type starting conformations which was rectified by re-docking with each of these compounds 
starting from the lowest energy β-strand conformation. However, some would still not dock 
with poses that met our criteria of having the three essential H-bonds, close warhead-
nucleophile distance, and low Glide and Emodel scores.  
 
Docking studies were then performed with the InducedFit Protocol, which takes up more 
computer time but was thought to be necessary because of the larger size of the macrocycles 
compared with the acyclic di-peptides we had previously studied. The InducedFit Protocol 
allows the active site to make small adjustments with respect to each docked ligand thereby 
simulating what effectively happens in a real enzyme. InducedFit docking showed that 
compounds A1, A3, A4, B1 and B3 could dock into the enzyme model with all the criteria 
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met. With this evidence compounds A1 and B1 were synthesized and tested in vitro and 
proved to inhibit m-calpain with IC50‟s of 3710 and 280 nM, respectively. This was sound 
evidence that the modelling and docking experiments were providing relevant information to 
guide the synthetic chemists to synthesizing appropriate compounds from the macrocyclic 
library. 
 
The ensembles of low energy conformers of the 288 compounds were mixtures of β-
strands and turn-type conformation. It was thought that by determining the Boltzmann 
weighted percentage of β-strands in each ensemble we could choose appropriate compounds 
with a propensity of adopting a β-strand conformation to model/dock. A program was written 
that could determine the Boltzmann weighted percentage of β-strand in each ensemble.  
 
Compounds in the library that displayed a >90% preference for a β-strand (A1, A2, H1, 
I9, P7, and P8) were then docked using the InducedFit Protocol (compounds A1 and A2 were 
docked previously). Compounds A1, H1, I9, P7, and P8 showed good docking 
characteristics. The best docked compound (H1) was synthesized and tested to have a 
moderate IC50 of 2400 nM. This again proved that the docking studies were a valuable tool in 
selection of potential inhibitors. 
 
Although the macrocycles synthesized and tested to date (A1, B1, and H1) were shown 
to inhibit m-calpain in vitro, they were not particularly potent, with the possible exception of 
B1 which was a reasonably good inhibitor. To investigate if we could increase the potency of 
the macrocycles we decided to replace the 4-fluorobenzyl sulphonamide capping group with 
a Cbz group to the core structures of compounds A1, B1, C1, and H1. The cores of A1, B1, 
and H1 were chosen as these three had proven to be moderate inhibitors of m-calpain. The 
4   Molecular modeling of cyclic inhibitors 
 
 139 
core of C1 was included as the previous docking studies had been inconclusive and it was an 
analogue of A1 and B1 with a larger macrocyclic ring. 
 
These four core structures with Cbz (compounds 4.9, 4.12, 4.15, and 4.18) were also 
modified to have a leucine (replacing valine) at the P2 position to give compounds 4.10, 4.13, 
4.16, and 4.19. Compounds 4.10, 4.13, 4.16, and 4.19 were then modified by replacing the 
aldehyde warhead with an alcohol to give compounds 4.11, 4.14, 4.17, and 4.20. These 
twelve compounds were docked into the enzyme model with the InducedFit Protocol. All the 
compounds with the exception of 4.20 docked in the appropriate manner. Compound 4.20 
was not expected to dock appropriately as the Boltzmann weighted percentage of conformers 
in a β-strand for this compound was calculated at 0% meaning it could not without a 
considerable energy cost  adopt this bioactive conformation. 
 
All the compounds except 4.9 and 4.15 were synthesized and tested including 4.20 (4.20 
was synthesized as a curiosity to see if the modelling was correct in its assumption that it 
would not be a good inhibitor of m-calpain). The modelling proved correct and 4.20 had a 
poor IC50 of 28000 nM. All the other tested compounds except 4.11 proved to be at least 
moderately good inhibitors with 4.12 and 4.13 being excellent inhibitors with IC50‟s of 85 
and 30 nM, respectively. Again the modelling/docking studies proved to be a valuable tool in 
deciding which compounds to synthesize. 
 
Compound 4.13 (Figure 4.31) the best compound in the in vitro test was also tested in 
vivo to evaluate its potential to retard the development of calcium-induced cortical cataracts 
in sheep lenses. The result proved that 4.13 could significantly retard cataract formation. 
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Figure 4.31: Structure of compound 4.13 (also known as Cat 811) 
 
Additional modification of the core structure of compound P8 was investigated. Cbz had 
been proven to be a better capping group than 4-fluorobenzyl sulphonamide in the previous 
study such that 4.13 and similar compounds were better inhibitors than their 4-fluorobenzyl 
sulphonamide analogues. The core structure of P8 with a Cbz group, compound 4.21, was 
proposed. The alkene of 4.21 was then oxidised to give the diol 4.22 and 4.23. It was 
expected that the diol groups would extend out of the active site pocket if the compounds 
docked appropriately and interact with the hydrophilic environment surrounding the active 
site. The docking experiments showed that compounds 4.21, 4.22, and 4.23 could dock with 
the key criteria. However, 4.22 and 4.23 docked with their diol groups occupying a normally 
hydrophobic area to the side of the active site pocket which could be unfavourable for 
binding, although all three compounds had very good Glide and Emodel scores. At the time 
of writing the compounds have been prepared but have not yet been tested in vitro. 
 
The docking of macrocyclic compounds by the InducedFit Protocol has proven to be a 
valuable tool in aiding the selection of compounds, from the 288 compound library, to 
synthesize. It also provided ideas for modification of the core macrocycles with the aim of 
designing more potent inhibitors of m-calpain. 
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Despite the model being based on a µ-calpain construct (1KXR) and our ultimate goal 
being the design of inhibitors of the cataract causing m-calpain, the model has been a success. 
An m-calpain model would have been a more appropriate model but this was not possible as 
there is no X-ray crystal structure of an active m-calpain. However, µ-calpain and m-calpain 
are very similar in their active site structure and most inhibitors of one form inhibit the other 
and this warranted the use of the µ-calpain construct as a model to perform docking 
experiments. Molecular modelling cannot be absolutely definitive because nature has too 
many variables but is a valuable tool in rational drug design and has the potential to get even 
more effective as appropriate flexibility is built into the enzyme model and computers and 
algorithms increase speed of the computations necessary. 
 
Future work would be focused on further docking experiments using the macrocyclic 
library of compounds to find more core structures that show potential as calpain inhibitors. 
These would be used to design compounds with modified capping groups, warheads, and P2 
side chains. I would also use the X-ray structures of µ-calpain constructs that have inhibitors 
bound in their active sites to develop a better model, one that could better predict the 
potential of compounds inhibitory qualities and differential selectivity between the calpains. 
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5 Drug penetration, in vivo testing, and crystallography 
 
5.1 Construction of a modified Ussing chamber  
 
To test the effectiveness of our inhibitors to reach their target (m-calpain in the eye lens) 
I designed a modified Ussing chamber in an attempt to measure the diffusion rates 
(penetration) of our inhibitor across a sheep's cornea. The cornea is a major barrier to 
delivery of drugs into the inner eye tissues.  
 
The Ussing chamber was originally invented by Hans Ussing to study ion transport 
through frog skin.
1, 2
 It consists of a chamber that holds the tissue and buffer solution, and 
electrical circuitry that measures resistance, current, and voltage so that the transport of ions 
across the tissue can be studied. For our purposes the electrical circuitry is not needed.  
 
Using an Ussing chamber borrowed from the biology department and data from similar 
cornea penetration experiments in the literature,
3
 we modified the chamber so that it would 
hold a sheep's cornea between the chamber‟s two sides.  
 
The plans for the construction of the modified Ussing chamber are shown in Figures 5.1-
5.3.  
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Figure 5.1: (Left) Side view cross sections of modified Ussing chamber showing the dimensions of the 
separated right and left-handed pieces. Grey areas depict hollowed out parts of the solid perspecs cylinder.  
Figure 5.2: (Right) Detail of the joint ends of the modified Ussing chamber. Grey areas depict hollowed out 
areas of perspecs (chamber connecting holes and prong holes). Black areas depict  prongs and the rubber O-ring. 
 
 
 
Each side of the chamber holds approximately 5mL and has small gas injection intakes to 
allow a 95% O2/5% CO2 gas to be bubbled through the buffer solutions. The two piece 
chamber is joined together with four prongs (pins). The tissue (cornea) is placed between the 
two sides of the chamber so that it covers (seals) the opening between the chambers two sides 
and the two sides of the chamber are held firmly in place with a specially designed vice grip .  
Right end side view 
Left end side view 
3mm 
12mm 
20mm 
60mm 
5mm 
50mm 
34mm 
15mm 
4mm 
14mm 
Right piece joint end, side and 
end view 
Left piece joint end, side and 
end view 
Rubber O-ring 
Alignment prongs 
Prong holes 
35mm 
40mm 
18mm 
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Figure 5.3:. Top views of each end of chamber with the grey areas depicting the openings to the hollowed out 
areas. Bottom diagram is of whole Ussing chamber setup in vice (black). O-ring is black and the grey areas are 
showing the hollowed out interior.  
 
 
5.2 Testing of inhibitors using the Ussing chamber to determine 
corneal penetration 
 
Two of our compounds (dialdehyde compound 3.26 and triazene compound 3.38a) and 
the lead compound 3.10 have been tested using the Ussing chamber to determine how much, 
if any, of these inhibitors can cross the cornea from the epithelial side (outside) to the 
endothelial side (inside) and are shown in Figure 5.4. 
 
 
 
 
 
Right piece top view 
Left piece top view 
Overall chamber in vice holder 
Vice holder 
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Figure 5.4; Structures used in Ussing chamber experiment. Lead compound 3.10, dialdehyde compound 3.26 
and the triazene compound 3.38a. 
 
The procedure is as follows: 
1. The chamber is partially submerged in a water bath at 35 ºC. 
2. The cornea of a freshly harvested sheep's eye is carefully excised and placed so the two 
sides of the chamber are separated from each other by the cornea. 
3. A solution of buffer A (5ml) saturated with a test compound at 35 ºC is placed into the 
epithelial side of the chamber. 
Buffer A contains; 
0.1% tween 80 
0.1%NaH2PO4.2H2O 
0.9% NaCl 
NaOH to adjust to pH 7.0 
  
4. A solution of buffer B (5ml) at 35 ºC is placed into the endothelial side of the chamber. 
Buffer B contains; 
 
0.0132% CaCl2 
0.04 KCl 
0.02% MgSO4.2H2O 
0.0187% NaH2PO4.2H2O 
0.787% NaCl 
0.1% glucose 
NaOH to adjust to pH 7.2 
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5. A 95% O2/5% CO2 gas (carbogen gas) is injected into both sides of the chamber at a 
rate of 2-3 bubbles per second. 
6. The chamber is kept at 35 ºC throughout experiment. 
7. 200µl aliquots from each side of the chamber are taken at regular intervals (every 30 
minutes) over 3 hours. 
8. The aliquots were examined by HPLC to determine the concentration of inhibitor in 
each aliquot. 
9. A plot of concentration of compound (inhibitor) versus time gives a qualitative measure 
of the diffusion rate of inhibitor through the sheep's cornea. 
  
The buffers are formulated differently to simulate the actual environment of the 
epithelial and endothelial sides of the cornea in a live sheep. 
 
The aliquots taken at 30min intervals were analysed by HPLC by Seth Jones and Dr 
Mathew Jones. However, the aliquots taken for all three compounds had no detectable traces 
of the respective compounds. The compounds were not able to cross the cornea in detectable 
(by HPLC) amounts over the 3 hour time period. 
 
5.3  In-vivo sheep trial results of compound 3.26 
 
Our collaborators at Lincoln University were given our dialdehyde compound 3.26 to 
conduct in vivo sheep trials. A ten week trial commenced in October 2004 using an eye drop 
formulation of compound 3.26, which had the following formula; 
0.1%  (w/w) compound 3.26 
14% EtOH 
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0.9% sodium chloride 
0.3%  hydroxypropyl methyl cellulose 
0.05%  disodium EDTA 
0.01%  benzalkonium chloride 
84.65% MilliQ purified water 
 
The formula of compound 3.26 was applied to the left eye of lambs with developing 
cataracts, leaving the right eye as an untreated control.  The development of cataracts was 
scored based on the scoring system in Figure 5.5 by a veterinary ophthalmologist two weeks 
before the start of the evaluation (t= -14) and three times during the eleven weeks of 
treatment (t = 10, 37, 67 days).   The mean score after each examination is shown in Figure 
5.6.   
 
 
Figure 5.5: One to seven cataract scoring system. (1) Anterior suture lines (2) Anterior & posterior suture lines 
(3) 0-33% cortical nuclear involvement (4) 33-66% cortical nuclear involvement (5) Greater than 66% cortical 
nuclear involvement (6) Total immature cataract (7) Total mature cataract  
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Figure 5.6: A plot of mean cataract scores for untreated and treated eyes 
 
Both eyes had the same cataract scores over the first 37 days. By the end of the 67 day trial 
the treated eye scored higher than the untreated eye. The trial had shown that the formula 
containing compound 3.26 did not retard cataract development in the trial conditions. The 
reason why no retardation was observed was postulated as being inadequate diffusion of the 
compound across the cornea which was likely due to the use of ethanol in the formulation 
that caused the eye drop to have a low surface tension. This caused most of the eye drop to be 
washed off the surface of the eye. 
 
To overcome this problem another trial was performed the following October which used 
compound 3.26 in an ointment formulation. It was hoped that the ointment would stay on the 
surface of the eye for a longer period of time in order to increase the amount of drug able to 
diffuse across the cornea. 
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The formula was as follows; 
1%  compound 3.26  
25% cetyl stearyl alcohol 
35% lanolin 
39% paraffin oil. 
 
Twenty-four two to three month old lambs were used for the trial. The left eye of each sheep 
was treated twice daily with twenty five milligrams of ointment containing 0.25 milligrams of 
compound 3.26.   
 
During the trial the cataracts progressed rapidly and by the end of the trial over half had 
mature cataracts (Figure 5.7) 
 
Figure 5.7: Results of the ointment containing compound 5 in the in-vivo cataract sheep trial. 
 
The graph in Figure 5.7 shows that after one month the treated eyes showed significant 
cataract retardation (significant in a paired t-test at p < 0.05). 
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Compared with the cataract development in the sheep used in this trial, human cataracts 
develop at a much slower rate, therefore, the significant retardation of the sheep cataracts 
after one month would be expected to be significantly longer for humans. However, by the 
end of the trial there was no significant difference between treated and untreated eyes. 
 
5.4 Crystallography 
 
An attempt to co-crystallize papain with a number of our best inhibitors using the 
hanging drop method was performed. The procedure for this was based on the methods used 
in J. LaLonde 1998.
4
  
 
The hanging drop procedure for this went as follows: 
(i) A reservoir solution was made up consisting of; 
0.1M Tris HCl pH 8.5 
0.5M Trisodium citrate 
20% PEG 600 
(ii)  Papain purchased from Sigma was centrifuged to remove buffer yielding a 35mg/ml 
solution in water. 
(iii)  0.3 M solutions of the 7 best inhibitors (3.10, 3.26, 3.27, 3.29, 3.31, 3.38a, and 3.38b) 
were made up in DMSO. 
(iv)  6 µl solution of papain, 2 μl solution of inhibitor, and 8 μl solution of precipitant 
(reservoir solution) were added together and placed on a cover slip. This procedure 
was repeated for each inhibitor in duplicate plus four blanks without an inhibitor. 
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(v) 1ml solution of reservoir was placed into each well. The cover slips with papain, 
inhibitor, and precipitant were overturned and sealed on top of the wells with paraffin 
to form a hanging drop over the reservoir solution. 
(vi) The wells were then placed in a refrigerator at 5 ºC. 
(vii) Regular checks were made to identify any crystals that may have formed. 
 
This procedure failed to produce any crystals. It is possible that the papain was not pure 
enough to produce crystals and it may be necessary to further purify the papain by affinity 
chromatography or dialysis. 
 
5.5 Conclusion 
 
The Ussing chamber experiment did not produce any results because the diffusion of the 
inhibitors across the sheep corneas was too slow or non-existent over the three hour 
experiment and consequently there was not enough of each inhibitor on the endothelial side 
of the chamber to be detected by HPLC. 
 
To overcome this detection problem in the future, the experiment could be run over night 
for 24 hours to determine if the inhibitors can cross the cornea over a longer period of time. 
Another possibility would be to label the inhibitors using a radioactive label. Commonly used 
radioisotopes used in this way are 
3
H, 
14
C, 
15
N, and 
18
O.
5
 An inhibitor synthesized with a 
radioisotope could then be used in the Ussing chamber diffusion experiment so that the 
concentration of radioactive inhibitor on the endothelial side could be measured. However, 
the equipment and resources needed to carry out such an undertaking could be expensive. 
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The in vivo sheep trial showed that drug formulation is a critical aspect for the treatment 
of cataract because of the fact that the inhibitors are easily washed away by the continuous 
flushing of the eye by tears as was seen in the first trial using ethanol. The formulation in the 
next trial proved to be better as the ointment was able to stick to the eye for a longer period of 
time which increased the likelihood of corneal penetration of the inhibitor. Treatment showed 
significant results after one month but this was not sustained over the entire trial. 
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6 Design of antimicrobials and herbicides 
 
6.1 Introduction 
 
Work was also performed examining specific targets in the shikimate pathway a pathway 
important in plants and microbes, but not observed in the animal kingdom.
1-3
 It is therefore a 
suitable pathway to block when designing a herbicide or antimicrobial since it would be 
expected to have no effect on humans or animals. This pathway has been successfully 
targeted by the herbicide glyphosate which binds the sixth enzyme in the shikimate pathway 
known as 5-enolpyruvylshikimate-3-phosphate-synthase (EPSP synthase).
2
 
 
Another enzyme in the shikimate pathway known as 3-dehydroquinase, which catalyses 
the third step, is a sensible target for inhibitor action (Figure 6.1). What makes it attractive is 
that two different enzymes have evolved, type I and type II and both catalyze the dehydration 
of 3-dehydroquinate to 3-dehydroshikimate, but each has a distinct mechanism of action.
4
 
The type I enzymes catalyze a cis-dehydration of 3-dehydroquinate via a covalent imine 
intermediate, while the type II enzymes catalyze a trans-dehydration via an enolate 
intermediate.
4
 Type II is involved in another pathway, known to occur in some organisms 
such as fungi, called the quinate pathway.
5
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Figure 6.1. Third step in the shikimate pathway by dehydroquinase type I and type II. 
 
As there are two distinct forms of the enzyme there is the opportunity to design inhibitors 
of one type that do not affect the other. This means that certain organisms that possess one 
type of enzyme could be selectively targeted.
1
 One such example is the infectious bacterium, 
Mycobacterium tuberculosis, which possesses only type II 3-dehydroquinase. Because most 
(if not all) bacteria associated with human natural flora have only type I, an inhibitor of type 
II should be an effective antibiotic against tuberculosis, and this is important since it does not 
upset the natural flora associated with the human body.   
 
There are a number of X-ray structures published including those of the apo-enzymes 
(without substrates) and those with known inhibitors bound. The most suitable ones 
investigated to date are PDB codes 1GU1, 1GU0, 1HOR, and 1HOS.
1, 6
  
 
6.2 Modeling studies of dehydroquinase 
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Five compounds (6.1-6.4) were synthesized in house by Dr Mary Gower as analogues of 
the known dehydroquinase inhibitors 6.5 and 6.6 (Figure 6.2). Compounds 6.1-6.4 were run 
through a conformational search to find low energy conformers using Protocol 3 in the 
Appendix. The lowest energy conformer of each compound and the X-ray structures of 
compounds 6.5 and 6.6 were used to initiate Glide docking into a model of the X-ray 
structure 1HOS. The model was produced using Protocol 7 in the Appendix. Glide docking 
was performed using Protocol 8 in the Appendix. 
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Figure 6.2. Chemdraw structures of compounds 6.1, 6.2, 6.3, 6.4, 6.5 (3-hydroxyimino-quinic acid), and 6.6 
(2,3-anhydro-quinic acid). 
 
The X-ray crystal structure of 3-hydroxyimino-quinic acid bound into the active site of 
dehydroquinase from Mycobacterium tuberculosis (MTDHQase) is shown in Figure 6.3 left 
(PDB code 1H0S). On the right of Figure 6.3 is the X-ray crystal structure of 2,3-anhydro-
quinic acid bound into the same enzyme (PDB code 1H0R). Both inhibitors form the same 
eight core H-bonds to the enzyme; one each from His 81, His 101, Ile 102, and Arg 112, and 
two each from Asn 75 and Ser 103. However, the oxime of 3-hydroxyimino-quinic acid can 
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form two additional H-bonds to Pro 11 and Arg 19 which are thought to contribute 
significantly to the binding and is why 3-hydroxyimino-quinic acid is more potent in vitro 
than 2,3-anhydro-quinic acid against dehydroquinase from M. tuberculosis (Table 6.1). 
 
Table 6.1 Docking data for compounds 6.1, 6.2, 6.3, 6.4, 6.5, and 6.6. All docked with Glide into model of 
MTDHQase (PDB code 1H0S). 
 
Compound Glide score Emodel score H-bonds Essential H-
bonds out of 
5 
Ki (µM) 
MTDHQase 
6.1 -6.4 -56.7 7 4 45±5 
6.2 -6.0 -54.5 7 4 425±75 
6.3 -6.7 -53.5 6 4 1100±100 
6.4 -6.3 -44.4 7 3 2000±600 
6.5 -7.6 -72.5 10 5 20±2 
6.6 -7.5 -60.7 8 5 200±20 
 
 
    
Figure 6.3. Left; X-ray crystal structure of 3-hydroxyimino-quinic acid (compound 6.5) bound into the active 
site of MTDHQase (PDB code 1H0S). Right; X-ray crystal structure of 2,3-anhydro-quinic acid (compound 6.6)  
bound into the same enzyme (PDB code 1H0R). 
 
The five hydrogen bonds to Ser103, Ile102, and Asn75 were deemed to be essential 
interactions as these are observed in all known co-crystallised structures with inhibitors of 
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this type. Consequently, these five hydrogen bonds were used as constraints in the docking of 
6.1-6.6. 
 
   
Figure 6.4. Best docked poses of 6.1 (left) and 6.2 (right) into 1H0S (MTDHQase). 
 
To make certain that the model was able to dock the compounds with good accuracy the 
compounds 6.5 and 6.6 were docked back into the model to give a „baseline‟ to work with in 
terms of the Glide and Emodel scores. 
 
Both compounds 6.5 and 6.6 dock into the model in almost the exact way as they are seen in 
their respective co-crystallised structures (Figure 6.3). The Glide scores and Emodel scores 
are both good and reflect the fact that compound 6.5 is more potent in vitro than compound 
6.6 (Table 6.1) as it has a better Glide and Emodel score and it has two extra H-bonds. 
 
Compound 6.1 can form seven H-bonds to the enzyme active site (Figure 6.4) and it has four 
out of the five essential H-bonds used as constraints in the docking. The other H-bonds are 
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two from the semicarbazone to Arg 108 and one from the 5-hydroxyl to His 81. The H-bond 
to His 81 is also observed in the crystal structures with compounds 6.5 and 6.6 bound (Figure 
6.3). The Glide score and Emodel score of -6.4 and -56.7, respectively, indicates good 
binding. In vitro tests showed that compound 6.1 was a potent inhibitor of type II 3-
dehydroquinase with a Ki of 45±5 µM (Table 6.1). This is almost as potent as the 3-
hydroxyimino-quinic acid which had a Ki of 20±2 µM and is more potent than the 2,3-
anhydro-quinic acid with a Ki of 200±20 µM (Table 6.1). 
 
Figure 6.4 shows that the thiosemicarbazone of 6.2 cannot form H-bonding to the side chain 
of Arg 108 as is seen with the semicarbazone of 6.1. However, it does form four out of the 
five essential H-bonds used as constraints in the docking and it has another three H-bonds 
from the three hydroxyl groups, one to Gly 77, one to Arg 19, and the other to Arg 112. 
Compound 6.2 has a slightly inferior Glide and Emodel score compared with compound 6.1 
and may indicate why compound 6.2 has a less potent Ki of 425±75 µM (Table 6.1). 
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6.3          6.4 
Figure 6.5. Best docked pose of 6.3 (left) and 6.4 (right) into 1H0S (MTDHQase). 
 
The hydroxyl group on the alkene of 6.3 can form a H-bond to the side chain of Arg 19 and 
the carboxyl group on the alkene of 6.4 forms a H-bond to the side chain of Arg 108 (Figure 
6.5). Compound 6.3 forms four out of five essential H-bonds but only six in total, while 6.4 
can only form three essential H-bonds and seven in total. Compound 6.4 also has a much 
lower Emodel score compared with the other compounds.  The loss of H-bonding for both 6.3 
and 6.4 and the lower Emodel scores is possibly why these compounds are significantly less 
potent than compound 6.1, the hydroxyimino-quinic acid 6.6, and the 2,3-anhydro-quinic acid 
6.5 with a Ki of 1100±100 µM for 6.3, and 2000±600 µM for 6.4 (Table 6.1). 
 
6.3 Conclusion 
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Four compounds (6.1-6.4) synthesized in house by Dr. Mary Gower were docked into the 
dehydroquinase model which was based on the X-ray crystal structure of type II 
dehydroquinase from M. Tuberculosis (1H0S). These were compared with two known 
inhibitors (6.5 and 6.6) which have published X-ray co-crystal structures with the enzyme.  
 
The compounds were also tested in vitro to give Ki values which gave data that was used 
to compare docking results. The results of the docking study showed that the known 
inhibitors (6.5 and 6.6) could re-dock back into their respective X-ray crystal structures in 
exactly the same way as they are seen in these structures and had excellent Glide and Emodel 
scores which gave a „baseline‟ to compare with the docking data from the in house 
compounds (6.1, 6.2, 6.3, and 6.4). These four compounds docked in a similar way to the two 
known inhibitors. Compound 6.1 had a Glide and Emodel score that was comparable to the 
known inhibitors, it formed a total of seven H-bonds with four  H-bonds being part of the 
essential five used as constraints in the docking. 6.1 proved to be the most potent of the in 
house compounds with a Ki of 45±5 µM which is almost as potent as compound 6.5. 
 
Compounds 6.2, 6.3, and 6.4 are less potent inhibitors. 6.2 is an order of magnitude less 
potent than 6.1 and has a slightly poorer Glide and Emodel score. 6.3 forms the least number 
of H-bonds to the active site and this may be why it has a poor Ki of 1100±100 µM. 6.4 is the 
least potent and this is reflected by it having the lowest Emodel score and only forming three 
out of the five essential H-bonds.  
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7 Molecular modelling to determine the absolute 
configuration of chrysosporide 
 
The following is data published in the Journal of Natural Products; 
Mitova, M. I.; Stuart, B. G.; Cao, G. H.; Blunt, J. W.; Cole, A. L. J.; Munro, M. H. G., 
Chrysosporide, a Cyclic Pentapeptide from a New Zealand Sample of the Fungus 
Sepedonium chrysospermum. J. Nat. Prod. 2006, 69, 1481-1484. 
 
7.1  Introduction 
A new cyclic pentapeptide, chrysosporide (7.1), was isolated from a New Zealand 
sample of the mycoparasitic fungus Sepedonium chrysospermum
1
 by bioactivity-guided 
fractionation. A planar structure was deduced by detailed spectroscopic analysis, and the 
absolute configurations of the amino acid residues were defined by Marfey's method.
2
 As 
both enantiomers of Leu occurred in chrysosporide, molecular mechanics calculations were 
applied to the analysis to distinguish between the possible structural isomers. Only the lowest 
energy conformers of the cyclo-(L-Val-D-Ala-L-Leu-L-Leu-D-Leu) isomer were in agreement 
with the observed NOEs, suggesting that this was the most probable amino acid sequence for 
chrysosporide (7.1).
3
  
 
Mycoparasitic fungi are a diverse and prolific source of compounds with potential 
therapeutic value.
3
 In our continuing search for new, bioactive metabolites from New Zealand 
fungi a strain of Sepedonium chrysospermum was investigated, as the culture extracts were 
cytotoxic against the P388 murine leukemia cell line.
4
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Figure 7.1: Left - structure of 7.1. Right – Lowest energy conformer of 7.1 from conformational search. 
7.2 Modelling 
 
Since attempts to crystallize chrysosporide (compound 7.1) were unsuccessful, the actual 
amino acid sequence of 7.1 was established from computer modelling and ROESY NMR 
studies. A conformational search of cyclopentapeptides, containing L-Val,  D-Ala, and all 
three possible combinations of two L-Leu and one D-Leu, was carried out with MacroModel
5
 
in combination with the OPLS2003 force field using a GB/SA water solvent model. An 
ensemble of conformers was collected that lay within 12 kJ of the global minima.  
 
The NOE is a function approximating to r-6 (r = H/H distance), which means for 
example that a H/H distance of 2 Å will give a much stronger NOE signal than a H/H 
distance of 3 Å. Boltzmann weighted r-6 total values were calculated for each of the inter-
residue H/H distance pairs within each ensemble of conformations within a 12 kJ/mol 
window. These values were used to compare the ensembles of conformers of the three 
structures against the experimentally measured NOEs.  
 
In the ROESY spectrum of 7.1 five strong inter-residue NOEs were observed. Table 7.1 
lists the global minima and the Boltzmann-weighted average of H/H distances for each 
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ensemble, along with the Boltzmann weighted r-6 values for each ensemble. Only cyclo-(L-
Val-D-Ala-L-Leu-L-Leu-D-Leu) (7.1) showed appropriate calculated distance data (relatively 
large values for the Boltzmann weighted r-6 total values) for the five NH/Hα and NH/NH 
combinations for which strong NOEs were observed. The other two structures have two or 
three calculated H/H values, which would not result in strong NOE signals (relatively small 
values for the Boltzmann weighted r-6 totals in Table 7.1). Therefore, the sequence of the 
isolated product was proposed to be cyclo-(L-Val-D-Ala-L-Leu-L-Leu-D-Leu).  
Table 7.1.  Selected Inter-residue H/H Distancesa in Diastereoisomeric Structures of 
Chrysosporide (1) Generated by Molecular Modeling 
  Hα(Ala)/ 
NH(Leu1) 
NH(Leu1)/ 
NH(Leu2) 
NH(Leu2)/ 
NH(Leu3) 
NH(Val)/ 
Hα(Leu3) 
Hα(Leu2)/ 
NHLeu3  
cyclo-(L-Val-D-
Ala-L-Leu-L-Leu-
D-Leu)  
GMDb  2.21  2.58  2.54  2.68  3.23  
  
BWA  
c  
2.22  2.71  3.04  2.6  2.86  
  
BWr-6, 
d  
2.5  0.96  0.69  1.31  1.05  
cyclo-(L-Val-D-
Ala-L-Leu-D-Leu-
L-Leu)  
GMD  2.52  4.32  4.51  3.36  2.17  
  BWA  2.5  4.13  4.46  3.42  2.2  
  BWr-6  0.53  0.03  0.02  0.08  1.05  
cyclo-(L-Val-D-
Ala-D-Leu-L-Leu-
L-Leu)  
GMD  3.48  4.03  4.47  3.56  2.13  
  BWA  3.26  3.42  3.95  3.53  2.65  
  BWr-6  0.42  0.35  0.11  0.1  1.13 
a Inter-residue NOEs between these protons were experimentally observed.b GMD - Global minima distance 
(Å).c BWA − Boltzmann-weighted average distance in ensemble (Å).d BWr-6 − Boltzmann-weighted r-6 total 
(r = H/H distance) 
 
Examination of the low-energy conformers of cyclo-(L-Val-D-Ala-L-Leu-L-Leu-D-Leu) as 
obtained by a conformational search using MacroModel
5
 showed intramolecular hydrogen 
bonding involving NH-Val and NH-Leu2 (Figure 7.2). However, this was a supportive, but 
not definitive in helping to resolve between the LLD, LDL DLL diastereomers, as all of the 
low-energy conformers of each possible structure formed the two H-bonds with equal 
frequency.  
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Figure 7.2: Low-energy conformer of cyclo-(L-Val-D-Ala-L-Leu-L-Leu-D-Leu) showing intramolecular H-
bonds. 
 
The molecular modelling of the three possible LLD, LDL, and DLL diastereomers of the 
cyclopentapeptides based on the NMR structural analysis were constructed in silico using the 
Maestro build function of the 2005 Schrödinger molecular modeling suite. A Monte Carlo 
multiple minimum (MCMM) conformational search of each structure was carried out with 
MacroModel 9.0 using the OPLS2003 force field with the GB/SA water solvent model. The 
criteria for convergence of each conformational search were the generation of 3000 starting 
conformations and a maximum of 5000 iterations in the energy miminization routine (PRCG 
method) for each conformer, collecting the ensemble of conformers within 12 kJ of the global  
established using the following expression: The five NH/Hα and NH/NH 
distances, for which strong NOEs were observed, were measured for all conformers within 
each ensemble. The Boltzmann weighted r-6 total was calculated for these five H/H distances 
within each ensemble, which gave virtual NOE values. These were used to compare the 
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modelled data with the experimental data in order to determine the amino acid sequence of 
chrysosporide (see Table 7.1).  
 
7.3 Conclusion 
 
Modelling showed the cyclo-(L-Val-D-Ala-L-Leu-L-Leu-D-Leu) to be the most likely 
diastereomer as the Boltzmann weighted distance data was calculated to be consistent with 
the observed NOEs. This was not the case with the other two possible diastereomers. 
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8 Appendix 
 
8.1 Protocol 1: Refinement of the Glide model from 1KXR 
 
The crystal structure of mini μ-calpain (pdb code 1KXR)1 was prepared by deleting 
water and ions, and mutation of Ser115->Cys115. This structure was minimised using the 
OPLS2001 force field with a GB/SA water model over 500 iterations. All residues within a 5 
Å distance to the calcium ions of the crystal structure were kept frozen during this 
minimisation. The RMSD of the minimised structure to the crystal structure was 0.96 Å for 
the heavy atoms (C, N, O, S). The structure was cleaned up by the Prime
2
 preparation and 
refinement tool. The cysteine sulphur of Cys115 was deprotonated. 
 
8.2 Protocol 2: Refinement of the InducedFit model from 1KXR 
 
The crystal structure of mini μ-calpain (pdb code 1KXR)1 was prepared by deleting 
water and ions, and mutation of Ser115->Cys115. This structure was minimised using the 
OPLS2001 force field with a GB/SA water model over 500 iterations. All residues within a 5 
Å distance to the calcium ions of the crystal structure were kept frozen during this 
minimisation. The RMSD of the minimised structure to the crystal structure was 0.96 Å for 
the heavy atoms (C, N, O, S). The structure was cleaned up by the Prime
2
 preparation and 
refinement tool. 
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8.3 Protocol 3: Conformational search methods 
 
Conformational searches were carried out with MacroModel 9.1
3
 to generate an 
ensemble of low energy conformers to establish a suitable starting conformation of each 
compound for the docking.
3
 The searches were conducted with the MCMM method using a 
GB/SA water model and the OPLS2001 force field, with 3000 steps for the conformational 
search and up to 5000 iterations for the minimisation of each generated structure. The 
minimisation was stopped with the default gradient convergence threshold of δ = 0.05 
kJ/(mol*Å). The default Polak-Ribiere Conjugate Gradient method was used for all 
minimisations.  
 
8.4 Protocol 4: Glide docking protocol 
 
Grid generation: The centre of the docking grid was defined as the centroid of the 
residues Cys115, Gly208, Gly271, and Lys347 and was generated with GLIDE 4.0 using 
default settings.
4
  The midpoint of each docked ligand was set to a 12 x 12 x 12 Å box. Van 
der Waals radii of the receptor atoms were scaled to 1.0. All other settings were default 
settings. 
 
Ligand docking: Ligands were docked flexibly in extra precision mode (XP) and with a 
van der Waals scaling of 0.8. The structure output was set to write out 10 poses per ligand. 
All other settings were default settings. 
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8.5 Protocol 5: InducedFit docking protocol 
 
The InducedFit
5
 docking script was opened in Maestro.
6
 
Glide enclosing box: The centre of the docking grid was defined as the centroid of the 
residues Cys115, Gly208, Gly271, and Lys347. The size was set at auto. 
Step 1: No protein preparation constrained refinement. Remove side chain of Lys347. 
Extra precision (XP). All other settings at default. 
Step 2: Default settings 
Step 3: Extra precision (XP). All other settings as default. 
 
8.6 Protocol 6: Computational methods used for diazo- and 
triazene-dipeptide aldehydes in section 3.4 
 
All molecular modeling experiments were conducted with the Schrödinger suite 2005. 
Conformational searches on 3.36a-d, 3.37a/b, and 3.38a/b were carried out with 
MacroModel 9.1 to generate an ensemble of low energy conformers to establish a suitable 
starting conformation of each compound for the docking.
3
 The searches of (E)-isomers were 
conducted with the MCMM method using a GB/SA water model and the OPLS2001 force 
field, with 3000 steps for the conformational search and up to 5000 iterations for the 
minimisation of each generated structure. The searches of (Z)-isomers were conducted with 
the MCMM method using a GB/SA water model and the MM2* force field where the C-
N=N-C dihedral angle was constrained to 8° with a force constant of 5000 kJ/mol. The 
minimisation was stopped with the default gradient convergence threshold of δ = 0.05 
kJ/(mol*Å). The default Polak-Ribiere Conjugate Gradient method was used for all 
minimisations. The centre of the docking grid was defined as the centroid of the residues 
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Cys115, Gly208, and Gly271 and was generated with GLIDE 4.0 using default settings.
4
 The 
centroid of Cys115, Gly208, Gly271, Glu349, and Asn253 was chosen for the docking grid 
generation and the size of the box was chosen by default. Van der Waals radii of the ligand 
and the protein atoms were scaled to 0.5. The side chain of Lys347 was removed for the 
docking and the 20 best poses of this S25 initial docking were retained. All protein residues 
within a 5 Å of the respective ligand pose were refined with PRIME 1.5, including Lys347.
5
 
The ligands were redocked with a van der Waals radius of 0.8 to the newly generated protein 
structures if within 30 kcal/mol of the best protein structure and only if within the top 20 
structures. For each of these protein structures, one ligand pose was kept for evaluation. 
 
 
8.7 Protocol 7: Preparation of dehydroquinase model 
 
The crystal structure of dehydroquinase (pdb code 1HOS) was prepared by deleting all 
water molecules. The structure was then cleaned up by the Prime preparation and refinement 
tool. The RMSD of the minimised structure to the crystal structure was 0.03 Å for the heavy 
atoms (C, N, O, S). 
 
8.8 Protocol 8: Glide docking protocol for dehydroquinase 
 
The receptor was scaled to 1.0 and the ligand identified. The centre of the docking grid 
was deemed to be the centre of the workspace ligand and the size of the ligands to be docked 
was those similar in size to the workspace ligand. Five H-bond constraints were identified; 
the H-bonds of which there are two to Ser103, one to Ile102, and two to Asn75. 
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8.9 Protocol 9: Bodipy assay 
 
The biological activity of the calpain inhibitors synthesized in this thesis was determined 
by measuring the inhibition constants (IC50) in an in vitro assay. IC50 indicates the 
concentration of inhibitor required to decrease the activity of the enzyme by 50%. 
 
Collaboration with Lincoln University allowed access to the materials required for the 
biological assay of cysteine protease inhibitors. The testing was performed by Dr Janna 
Nikkel and others in our research group. An established assay protocol for the determination 
of m-calpain inhibition based on a fluorogenic methodology used by Thompson et al
7
 was 
used. This assay protocol utilises casein, a water soluble protein, labelled with the 
fluorophore 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-sindacene-3-propionic acid 
(BODIPY). Fluorescence increases as proteolysis of the substrate (casein) occurs. Without 
proteolysis, fluorescence is not observed as adjacent intramolecular fluorophores cause auto-
quenching of fluorescence. Thus the inhibitory activity of a proposed inhibitor can be 
measured by calculating the change in fluorescence over a known period of time. m-Calpain 
and μ-calpain were partially purified from sheep lung by ion-exchange chromatography and 
diluted to give a linear response over the course of the assay.  
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